TWI338694B - Novel compounds - Google Patents
Novel compounds Download PDFInfo
- Publication number
- TWI338694B TWI338694B TW093120707A TW93120707A TWI338694B TW I338694 B TWI338694 B TW I338694B TW 093120707 A TW093120707 A TW 093120707A TW 93120707 A TW93120707 A TW 93120707A TW I338694 B TWI338694 B TW I338694B
- Authority
- TW
- Taiwan
- Prior art keywords
- oxo
- oxy
- methyl
- difluoro
- diene
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 114
- -1 Carboxylic acid cyano oxime ester Chemical class 0.000 claims description 77
- 239000002253 acid Substances 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 41
- 150000002148 esters Chemical class 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 26
- 239000007789 gas Substances 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 239000000048 adrenergic agonist Substances 0.000 claims description 14
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 239000000734 parasympathomimetic agent Substances 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 208000010668 atopic eczema Diseases 0.000 claims description 8
- 230000002757 inflammatory effect Effects 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 8
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- 150000001993 dienes Chemical class 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
- 239000000739 antihistaminic agent Substances 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 5
- 230000000172 allergic effect Effects 0.000 claims description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 125000003107 substituted aryl group Chemical group 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 230000001387 anti-histamine Effects 0.000 claims description 4
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 claims description 4
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 150000004702 methyl esters Chemical class 0.000 claims description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 4
- 239000000052 vinegar Substances 0.000 claims description 4
- 235000021419 vinegar Nutrition 0.000 claims description 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 3
- 229960005475 antiinfective agent Drugs 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003380 propellant Substances 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000006184 cosolvent Substances 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 2
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 claims description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 2
- 125000004673 propylcarbonyl group Chemical group 0.000 claims description 2
- 229930002330 retinoic acid Natural products 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 229960001727 tretinoin Drugs 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 2
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims 2
- JCHUCGKEGUAHEH-UHFFFAOYSA-N 1,1,2,2-tetramethylcyclopropane Chemical compound CC1(C)CC1(C)C JCHUCGKEGUAHEH-UHFFFAOYSA-N 0.000 claims 1
- KSJBHWGZQXGMNL-UHFFFAOYSA-N 1,2,2,3-tetramethylcyclopropane-1-carboxylic acid Chemical compound CC1C(C)(C)C1(C)C(O)=O KSJBHWGZQXGMNL-UHFFFAOYSA-N 0.000 claims 1
- OFJBYLCQNJHFMI-UHFFFAOYSA-N 2,5-dihydro-1,2-oxazole Chemical compound C1ONC=C1 OFJBYLCQNJHFMI-UHFFFAOYSA-N 0.000 claims 1
- MLIREBYILWEBDM-UHFFFAOYSA-M 2-cyanoacetate Chemical compound [O-]C(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-M 0.000 claims 1
- HDBQZGJWHMCXIL-UHFFFAOYSA-N 3,7-dihydropurine-2-thione Chemical compound SC1=NC=C2NC=NC2=N1 HDBQZGJWHMCXIL-UHFFFAOYSA-N 0.000 claims 1
- PGIBJVOPLXHHGS-UHFFFAOYSA-N Di-n-decyl phthalate Chemical compound CCCCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCCCC PGIBJVOPLXHHGS-UHFFFAOYSA-N 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical class [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 230000003266 anti-allergic effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- GTBRTGPZZALPNS-MXHVRSFHSA-N cyanoketone Chemical compound C1C=C2C(C)(C)C(=O)[C@H](C#N)C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GTBRTGPZZALPNS-MXHVRSFHSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 239000008249 pharmaceutical aerosol Substances 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 229940071127 thioglycolate Drugs 0.000 claims 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 claims 1
- 239000000543 intermediate Substances 0.000 description 66
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 31
- 206010057190 Respiratory tract infections Diseases 0.000 description 31
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 26
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- 239000012453 solvate Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 11
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000443 aerosol Substances 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 239000003862 glucocorticoid Substances 0.000 description 7
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 239000004305 biphenyl Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical group [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 125000002877 alkyl aryl group Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 229910052707 ruthenium Inorganic materials 0.000 description 4
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 150000004678 hydrides Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 3
- VWZPIJGXYWHBOW-UHFFFAOYSA-N otilonium bromide Chemical compound [Br-].CCCCCCCCOC1=CC=CC=C1C(=O)NC1=CC=C(C(=O)OCC[N+](C)(CC)CC)C=C1 VWZPIJGXYWHBOW-UHFFFAOYSA-N 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229960004017 salmeterol Drugs 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 2
- ISBSSBGEYIBVTO-TYKWNDPBSA-N (20R,22R)-20,22-dihydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@](C)(O)[C@H](O)CCC(C)C)[C@@]1(C)CC2 ISBSSBGEYIBVTO-TYKWNDPBSA-N 0.000 description 2
- TWHNMSJGYKMTRB-KXYUELECSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 TWHNMSJGYKMTRB-KXYUELECSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 2
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 2
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 2
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N anhydrous diethylene glycol Natural products OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- JVMKZHYSVDTFED-UHFFFAOYSA-N bicyclo[3.2.1]octane hydroiodide Chemical compound I.C1C2CCC1CCC2 JVMKZHYSVDTFED-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960001803 cetirizine Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229960001022 fenoterol Drugs 0.000 description 2
- 229960003592 fexofenadine Drugs 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 229960002848 formoterol Drugs 0.000 description 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229940080818 propionamide Drugs 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 229960003855 solifenacin Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960000195 terbutaline Drugs 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229950000339 xinafoate Drugs 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PUNXVEAWLAVABA-UHFFFAOYSA-N 1,2,3,4-tetrahydroanthracene;1,2,5,6-tetrahydroanthracene Chemical compound C1=CC=C2C=C(CCCC3)C3=CC2=C1.C1=CCCC2=C1C=C1CCC=CC1=C2 PUNXVEAWLAVABA-UHFFFAOYSA-N 0.000 description 1
- NDZYPHLNJZSQJY-QNWVGRARSA-N 1-(5-acetyl-4-methyl-1,3-thiazol-2-yl)-3-[(1r,2s)-2-[[(3s)-3-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]cyclohexyl]urea Chemical compound CC1=C(C(=O)C)SC(NC(=O)N[C@H]2[C@@H](CCCC2)CN2C[C@H](CC=3C=CC(F)=CC=3)CCC2)=N1 NDZYPHLNJZSQJY-QNWVGRARSA-N 0.000 description 1
- STHHLVCQSLRQNI-UHFFFAOYSA-N 1-azabicyclo[3.2.1]octane Chemical compound C1C2CCN1CCC2 STHHLVCQSLRQNI-UHFFFAOYSA-N 0.000 description 1
- QZOPRMWFYVGPAI-UHFFFAOYSA-N 1-chloroindole Chemical compound C1=CC=C2N(Cl)C=CC2=C1 QZOPRMWFYVGPAI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- PPHYVGLPHUNUHS-UHFFFAOYSA-N 2-hydroxysulfanyl-7H-purine Chemical compound N1=C(N=C2N=CNC2=C1)SO PPHYVGLPHUNUHS-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 description 1
- NAZPXKCJDZOQEJ-UHFFFAOYSA-N 3-oxopentanedinitrile Chemical compound N#CCC(=O)CC#N NAZPXKCJDZOQEJ-UHFFFAOYSA-N 0.000 description 1
- YSWBFLWKAIRHEI-UHFFFAOYSA-N 4,5-dimethyl-1h-imidazole Chemical compound CC=1N=CNC=1C YSWBFLWKAIRHEI-UHFFFAOYSA-N 0.000 description 1
- CVDXFPBVOIERBH-JWQCQUIFSA-N 4-[(4ar,10bs)-9-ethoxy-8-methoxy-2-methyl-3,4,4a,10b-tetrahydro-1h-benzo[c][1,6]naphthyridin-6-yl]-n,n-di(propan-2-yl)benzamide Chemical compound N([C@@H]1CCN(C)C[C@@H]1C=1C=C(C(=CC=11)OC)OCC)=C1C1=CC=C(C(=O)N(C(C)C)C(C)C)C=C1 CVDXFPBVOIERBH-JWQCQUIFSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 description 1
- VLHPVJOKZJFJHZ-UHFFFAOYSA-N 5-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxocyclohexane-1-carbonitrile Chemical compound FC(F)OC1=CC=C(C2CC(C(=O)CC2)C#N)C=C1OCC1CC1 VLHPVJOKZJFJHZ-UHFFFAOYSA-N 0.000 description 1
- AMGNUIPDCBVJPO-UHFFFAOYSA-N 5-bromobicyclo[3.2.1]octane Chemical compound C1C2CCC1(Br)CCC2 AMGNUIPDCBVJPO-UHFFFAOYSA-N 0.000 description 1
- QZLYKIGBANMMBK-UGCZWRCOSA-N 5α-Androstane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- MRHCSNNEUHXNIC-UHFFFAOYSA-N 9-benzylpurin-6-amine Chemical class C1=NC=2C(N)=NC=NC=2N1CC1=CC=CC=C1 MRHCSNNEUHXNIC-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- HHBXLTVZVWIYHF-UHFFFAOYSA-N C(C1)C2CCCC1C2.N.Br.Br.Br Chemical compound C(C1)C2CCCC1C2.N.Br.Br.Br HHBXLTVZVWIYHF-UHFFFAOYSA-N 0.000 description 1
- DQJQUGMVFNPJHK-UHFFFAOYSA-N C(CCCCCCCCC)C1(C(C1(CCCCCCCCCC)CCCCCCCCCC)C(=O)O)CCCCCCCCCC Chemical compound C(CCCCCCCCC)C1(C(C1(CCCCCCCCCC)CCCCCCCCCC)C(=O)O)CCCCCCCCCC DQJQUGMVFNPJHK-UHFFFAOYSA-N 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- QGBIFMJAQARMNQ-QISPFCDLSA-N C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O QGBIFMJAQARMNQ-QISPFCDLSA-N 0.000 description 1
- HWUPDMFSGDXFMI-UHFFFAOYSA-N C1CCCCC1.[C] Chemical compound C1CCCCC1.[C] HWUPDMFSGDXFMI-UHFFFAOYSA-N 0.000 description 1
- 108010059108 CD18 Antigens Proteins 0.000 description 1
- 102000017926 CHRM2 Human genes 0.000 description 1
- 102000017925 CHRM3 Human genes 0.000 description 1
- 101150060249 CHRM3 gene Proteins 0.000 description 1
- ZXAJPHVFLRHHTB-UHFFFAOYSA-N CNNC.C(COCCO)O Chemical compound CNNC.C(COCCO)O ZXAJPHVFLRHHTB-UHFFFAOYSA-N 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101150012960 Chrm2 gene Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical group FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 1
- FCYKAQOGGFGCMD-UHFFFAOYSA-N Fulvic acid Natural products O1C2=CC(O)=C(O)C(C(O)=O)=C2C(=O)C2=C1CC(C)(O)OC2 FCYKAQOGGFGCMD-UHFFFAOYSA-N 0.000 description 1
- 229940123127 Glucocorticoid agonist Drugs 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 101000622123 Homo sapiens E-selectin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 229940123134 Nitric oxide inhibitor Drugs 0.000 description 1
- DVEPYRKDVPDIBE-UHFFFAOYSA-N OSC=1NC2=CC=CC=C2C=1 Chemical compound OSC=1NC2=CC=CC=C2C=1 DVEPYRKDVPDIBE-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 101150098694 PDE5A gene Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- VPMWDFRZSIMDKW-YJYMSZOUSA-N Salmefamol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 VPMWDFRZSIMDKW-YJYMSZOUSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- XBDYBAVJXHJMNQ-UHFFFAOYSA-N Tetrahydroanthracene Natural products C1=CC=C2C=C(CCCC3)C3=CC2=C1 XBDYBAVJXHJMNQ-UHFFFAOYSA-N 0.000 description 1
- DQHNAVOVODVIMG-UHFFFAOYSA-M Tiotropium bromide Chemical compound [Br-].C1C(C2C3O2)[N+](C)(C)C3CC1OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- OEXHQOGQTVQTAT-SSZRJXQFSA-N [(1r,5s)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] (2r)-3-hydroxy-2-phenylpropanoate Chemical compound C1([C@H](CO)C(=O)OC2C[C@H]3CC[C@@H](C2)[N+]3(C)C(C)C)=CC=CC=C1 OEXHQOGQTVQTAT-SSZRJXQFSA-N 0.000 description 1
- VGXACJMXDYPFDB-SXMMONRFSA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] (2s)-2-(hydroxymethyl)-4-[(r)-methylsulfinyl]-2-phenylbutanoate Chemical compound C1([C@@](CO)(C(=O)O[C@@H]2C3CCN(CC3)C2)CC[S@](=O)C)=CC=CC=C1 VGXACJMXDYPFDB-SXMMONRFSA-N 0.000 description 1
- RVCSYOQWLPPAOA-CVPHZBIISA-M [(5s)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride Chemical compound [Cl-].[N+]12([C@H]3CCC2CC(C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 RVCSYOQWLPPAOA-CVPHZBIISA-M 0.000 description 1
- CDKNUFNIFGPFSF-AYVLZSQQSA-N [(8s,9s,10r,11s,13s,14s,17r)-11-hydroxy-10,13-dimethyl-3-oxo-17-(2-propanoylsulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CSC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O CDKNUFNIFGPFSF-AYVLZSQQSA-N 0.000 description 1
- AHOIXWDZUQMNJD-UHFFFAOYSA-N [Br].CC#N Chemical compound [Br].CC#N AHOIXWDZUQMNJD-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- XLAKJQPTOJHYDR-QTQXQZBYSA-M aclidinium bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 XLAKJQPTOJHYDR-QTQXQZBYSA-M 0.000 description 1
- 229960005012 aclidinium bromide Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- YADDYKXZVNQFBH-UHFFFAOYSA-N argon;hydrobromide Chemical compound [Ar].Br YADDYKXZVNQFBH-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229940098165 atrovent Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- KEWHKYJURDBRMN-XSAPEOHZSA-M chembl2134724 Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-XSAPEOHZSA-M 0.000 description 1
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- USJRLGNYCQWLPF-UHFFFAOYSA-N chlorophosphane Chemical compound ClP USJRLGNYCQWLPF-UHFFFAOYSA-N 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229950001653 cilomilast Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 239000000430 cytokine receptor antagonist Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229940076405 detrol Drugs 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940099170 ditropan Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940013628 enablex Drugs 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940095100 fulvic acid Drugs 0.000 description 1
- 239000002509 fulvic acid Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 description 1
- 230000003314 glucocorticoidlike Effects 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- UKACHOXRXFQJFN-UHFFFAOYSA-N heptafluoropropane Chemical compound FC(F)C(F)(F)C(F)(F)F UKACHOXRXFQJFN-UHFFFAOYSA-N 0.000 description 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960001508 levocetirizine Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- UFFQZCPLBHYOFV-UHFFFAOYSA-N n,n-diethyldecan-1-amine Chemical compound CCCCCCCCCCN(CC)CC UFFQZCPLBHYOFV-UHFFFAOYSA-N 0.000 description 1
- DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 229960002259 nedocromil sodium Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- SRHHXHOIKKDDOY-UHFFFAOYSA-N octane;hydroiodide Chemical compound I.CCCCCCCC SRHHXHOIKKDDOY-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229960000426 otilonium bromide Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- LCELQERNWLBPSY-SPJIBDPASA-M oxitropium Chemical compound [Br-].C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@@H](C2)[C@H]2[C@@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-SPJIBDPASA-M 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 229960000797 oxitropium Drugs 0.000 description 1
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical group O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960004633 pirenzepine Drugs 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229950010090 pumafentrine Drugs 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 229950000915 revatropate Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229950004432 rofleponide Drugs 0.000 description 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229950001879 salmefamol Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L sodium sulphate Substances [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940046810 spiriva Drugs 0.000 description 1
- DQHNAVOVODVIMG-RGECMCKFSA-M spiriva Chemical compound [Br-].C([C@@H]1[N+]([C@H](C2)[C@@H]3[C@H]1O3)(C)C)C2OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-RGECMCKFSA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 229960005383 terodiline Drugs 0.000 description 1
- UISARWKNNNHPGI-UHFFFAOYSA-N terodiline Chemical compound C=1C=CC=CC=1C(CC(C)NC(C)(C)C)C1=CC=CC=C1 UISARWKNNNHPGI-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical group C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 description 1
- 229960001530 trospium chloride Drugs 0.000 description 1
- RVCSYOQWLPPAOA-DHWZJIOFSA-M trospium chloride Chemical compound [Cl-].[N+]12([C@@H]3CC[C@H]2CC(C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 RVCSYOQWLPPAOA-DHWZJIOFSA-M 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940063390 vesicare Drugs 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011995 wilkinson's catalyst Substances 0.000 description 1
- UTODFRQBVUVYOB-UHFFFAOYSA-P wilkinson's catalyst Chemical compound [Cl-].C1=CC=CC=C1P(C=1C=CC=CC=1)(C=1C=CC=CC=1)[Rh+](P(C=1C=CC=CC=1)(C=1C=CC=CC=1)C=1C=CC=CC=1)P(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 UTODFRQBVUVYOB-UHFFFAOYSA-P 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
1338694 九、發明說明: 【發明所屬之技術領域】 本發明係關於雄烷激素系列之類糖皮質素受體促效劑之 化合物及其制法。本發明亦關於含該化合物之醫藥調配物 及其治療上之應用,尤其是治療發炎及過敏性症狀。 【先前技術】 具有消炎性質之糖皮質素類固醇爲已知,且廣泛用於治 療發炎失凋或疾病如氣喘及關節炎。然而,本發明者已經 確認一種新賴系列之糖皮質素類固醇。 【發明内容) 因,’本㈣之—目的係提供-種下式⑴之化合物,或 其醫藥可接受性鹽或其溶劑化物
其中 X代表0或S ; R|代表Ci-6烷基、c3,s環烷基、 基,其任一個均可視情况以一 代,或R|代表芳基、經取代之; 基,其任一 、經取代之芳基、 芳基; 環炫基甲基或C3.8環烯 或•夕個曱基或鹵素原子取 :'雜芳基或經取代之雜 94506.doc 1338694 I代表氫、甲基,其可爲㈣結構,或爲亞甲基; 爲㈣或不@ ’且各獨立代表氫、_素或甲基 且代表單鍵或雙鍵。 【實施方式】 溶劑化物之實例包含水合物。 此後參考之本發明化合物包含式⑴之化合物及其溶劑化 之所有立體異構物 應瞭解本發明之範圍包含式(I)化合物 及其混合物。 較好,無水之立體異構物將以式⑴化合物之代表例顯示。 較好,X代表0。 K代表CN0烷基之較佳實例包含2,2_二甲基丙基。
Ri代表C3-8環烷基之較佳實例包含環丙基、環丁基、環戊 基及環己基,及經取代之衍生物’如甲基環丙基(例如卜甲 基環丙基)、一氣一甲基環丙基(例如2,2•二氣_3,3二甲基環 丙基)及四甲基環丙基(例如2,2,3,3-四甲基環丙基)〇 Ri代表C3-8環烷基甲基之較佳實例包含環戊基甲基。
Ri代表C3·8環烯基之較佳實例包含含1或多個雙鍵之烯基 (不爲芳系基)如環己烯基例如環己_2,3-烯基。 依某些具體例’較好R,代表經取代之芳基。 R丨代表經取代芳基之較佳實例包含4 ·(二乙基胺基)磺醯 基笨基、2,6-二氟苯基、4_甲氧基苯基、3_二氟甲基硫笨基 及4-氰基苯基。
Ri代表雜環基之較佳實例包含嗤啉_2_基。 94506.doc 代表經取代雜環基之較佳實例包含5_氣_4_曱氧基_嘧 吩-3-基’ 2_異丙基十3_p塞唑冬基、5_三氟甲基呋。南冬基、 %甲基俩基_,塞吩_2•基、5•甲基硫基_切_2•基及5-乙基· 異咩唑-3-基。 取mi爲視情況以―或多個甲基及/或函素基取代之c3 8 %垸基。最好Rl爲視情況以—或多個甲基或氣基取代之C" 環烷基。 R1代表之最佳基包含四曱基環丙基、二氣二甲基環丙 基、被己基及環戍基甲I,尤其是2,2义3_四甲基環丙基及 2’2-二氣-3,3-二甲基環丙基,最好爲2,2,3,3_四甲基環丙基。 較好R_2代表甲基,尤其是α結構中之甲基。 較佳之式⑴化合物爲其中之1及尺4(可爲相同或不同)分 別代表氫、甲基、氟或氣,且最好爲氫或氟之化合物。最 佳之化合物爲其中尺3及&均爲氟之化合物。 較好,=·代表雙鍵。 需瞭解本發明涵蓋上述最佳與較佳基之所有結合。 較佳之式⑴化合物包含: 6〇ί,9α•二氟 _u尽-羥基-16α-甲基-3-氧代 _17α_(2,2,3,3-四 甲基環丙基羰基)氧基-雄_丨,4_二烯_丨7心羥硫代酸s_氰基甲 酯; i7〇K4-[(二乙基胺基)續酿基]字醯基)氧基-他⑽·二氟 -11/3-羥基-ΐ6α;-曱基_3_氧代-雄·L4 —二烯_17j8_羥硫代酸s-氰 基曱酯; 1 7α-(5-氣-4-甲氧基”塞吩羰基)氧基_6α,9☆二氟_ i t心 94506.doc 1338694 羥基-1 6α-甲基-3-氧代-雄-1,4·二烯-17/3-羥硫代酸S-氰基曱 西旨, 6α,9α-二氟-11/5-羥基-16os 甲基-3 -氧代-17〇!-(2,2,3,3-四 甲基環丙基羰基)氧基-雄-1,4-二烯-17/?-羧酸氰基曱酯; 17α·(環己基羰基)氧基-6α,9α-二氟-11/3-羥基-16α-甲基 -3-氧代-雄-1,4-二烯-17/3-羧酸氰基甲酯; <3α,9α_二氟-17α-(2,6-二氟苄醯基)氧基-11|S-羥基-16α-甲 基-3-氧代-雄-1,4-二烯-17(3-羧酸氰基甲酯; 6α,9α-二氟-llj3-羥基-17α-(4-曱氧基芊醯基)氧基-16α-曱 基-3-氧代-雄-1,4-二烯-17j8-羧酸氰基甲酯; 17α-(4-氰基芊醯基)氧基-6α,9α-二氟-11/3-羥基-16α-甲基 -3-氧代-雄-1,4-二烯-17/5-羧酸氰基曱酯; 17ο:-(環戊基甲基羰基)氧基-6α,9α-二氟-11/3-羥基-16α-甲 基-3-氧代-雄-1,4-二烯-17/3-羧酸氰基甲酯; 6α,9α-二氟-17α-(3,3-二甲基丁醯基)氧基-11卢-羥基-16α-甲基-3-氧代-雄-1,4-二烯-17ι8-羧酸氰基曱酯; 6〇:,9〇:-二氟-11/5-羥基-17α-(2-異丙基-1,3-〇塞唑-4-羰基)氧 基-16α-曱基-3-氧代-雄-1,4-二烯-17)8-羧酸氰基甲酯; 6〇!,9〇:-二氟- lljS-羥基-16α-甲基-3-氧代 _ΐ7α-(喳啉-2-羰 基)氧基-雄-1,4-二烯-17/3-羧酸氰基曱酯; 6α,9α-二氟-11/3-羥基-16α-甲基-3-氧代·ΐ7α-(5-三氟甲基 -呋喃-2-羰基)氧基-雄-1,4-二烯-17^-羧酸氰基甲酯; 6α,9α-二氟-11/3-羥基-16α-甲基-17α-(5-甲基磺醯基塞吩 -2-羰基)-3-氧代-雄-1,4-二烯-17/3-羧酸氰基甲酯; 94506.doc 6α,9α-二氟-11/5-羥基-16α-甲基- Πα-(5 -甲基硫基塞吩 -2-羰基)氡基-3-氧代-雄-1,4-二烯-17)3-羧酸氰基甲酯; 6 〇f,9 α-二氟-17 α-(5 -乙基-異p号°坐-3 -幾基)氧基- lljS-經基 -16 α:-甲基-3-氧代-雄-1,4-二稀-17/?-缓酸氰基甲醋; 9α-氟-11/5-羥基-16|3-甲基-3-氡代-ΐ7α-(2,2,3,3-四甲基環 丙基羰基)氧基-雄-1,4-二烯-17/3-羧酸氰基甲酯; 6α,9ο:-二氟- Ilj3-羥基-16α-甲基-3-氧代-17α-(2,2,3,3-四 甲基環丙基羰基)氧基-雄-1,4-二烯-17/3-羧酸氰基甲酯; 17 〇ί-(5-氣-4-甲氧基塞吩-3-幾基)氧基- 6 ο:,9 〇:-二氟-11/?-經基-16ο;-甲基-3-氧代-雄-1,4 -二稀-17/3-叛酸氣基甲醋; 17α-(2,2-二氣-3,3-二甲基環丙基羰基)氧基-6α,9α-二氟 -11尽-羥基-16α-甲基-3-氧代-雄-1,4-二烯-17/3-羧酸氰基甲 酯; 1 7α-(2,2-二氣-3,3-二甲基環丙基叛基)氧基-6α,9α-二氟 -11心羥基-16α-甲基-3-氧代-雄-1,4-二烯-17/3-羥硫代酸S-氰 基曱酯; 1 7α-(環己基羰基)氧基-6〇;,9〇:-二氟-11尽_羥基-16α-曱基 -3 -氧代-雄-1,4 -二稀-1 7/3-經硫代酸S -氰基甲自旨; 6α,9α-二氟-11点-羥基-16α-甲基-17〇;·(5 -甲基磺醯基-唼吩 -2-幾基)氧基-3-氧代-雄-1,4-二晞-17/3-經硫代酸S-氰基曱 酯; 6α,9α-二氟-11/3-羥基-16α-甲基-3-氧代470:-(5-三氟甲基 -呋喃-2-羰基)氧基-雄-1,4-二烯-17/?-羥硫代酸S-氰基曱 酯;及 94506.doc -10- 038694 6α,9α-二氟-17α:-(3-(二氟甲基硫基)苄酿基)氧基-1 If羥 基_16α-曱基-3-氧代-雄-i,4-二烯_ι7ι3-羥硫代酸S-氰基曱 m » 最佳之化合物爲: 6α,9α-二氟-11心羥基-16α-甲基-3-氧代 _17«-(2,2,3,3-四 甲基環丙基羰基)氧基-雄-1,4-二烯-17/3-羥硫代酸S-氰基甲 酯; 6α,9α-二氟-11/5-羥基-16α-甲基-3-氧代 _17〇;-(2,2,3,3-四 甲基環丙基羰基)氧基-雄-1,4-二烯-17心羧酸氰基曱酯; 9α-氟-11/3-羥基-16/5-甲基-3-氧代·ΐ7α-(2,2,3,3-四甲基環 丙基羰基)氧基-雄-1,4-二烯-17/3-羧酸氰基甲酯; 17〇!-(環己基羰基)氧基-6〇;,9〇!-二氟-11/5_羥基-16(^-甲基 -3-氧代-雄-1,4-二烯-17/?-羧酸氰基甲酯; 1 7α-(環戊基甲基獄基)氧基-6〇:,9〇:-二氟-11尽_經基_ 16α-甲 基-3-氧代-雄-1,4-二烯-17/3-羧酸氰基曱酯; 6α,9α-二氟-17α-(3,3-二甲基 丁醯基)氧基-i lj(3·羥基·16α· 甲基-3-氧代-雄-1,4 -二稀-17/3-叛酸氰基曱g旨; 6α:,9α-二氟-17〇ί-(3-(二氟甲基硫基)芊醯基)氧基-11(8_羥 基-16α-甲基-3 -氧代-雄-1,4-二稀-1 7jS-經硫代酸S-氰基甲 酯; 17α-(環己基羰基)氧基-6α,9ο:-二氟-11/3-羥基-16α-甲基 -3-氧代-雄-1,4-二烯-1 7/5-羥硫代酸S-氰基甲酯; 6〇;,9〇!-二氟-170:-(5-乙基-異呤唑-3-羰基)氧基- η心羥基 -16 ο:-曱基-3-氧代-雄-1,4-二稀-17尽-緩酸氰基曱§旨; 94506.doc -11 - 338694 6a,9tx-二氟-11/3-羥基-16ο:-甲基-Πα-(5-甲基硫基-嘧吩 -2-羰基)氧基-3-氧代-雄_ι,4-二烯— 170-羧酸氰基甲酯; 6α,9ο;-二 H-11/3-羥基-l7〇;-(2-異丙基-1,3-ρ塞唑-4-羰基)氧 基-16α-曱基-3-氧代-雄-l,4-二烯-丨7卜羧酸氰基曱酯; 17α-(2,2-二氣-3,3-二甲基環丙基羰基)氧基_6α,9α•二氟 -11卢-羥基-16α-曱基-3-氧代-雄-1,4-二烯-17/3-羥硫代酸S-氰 基甲酯;及 17α-(2,2-二氯-3,3-二甲基環丙基羰基)氧基_6α,9α_二氟 -11卢-羥基-16α-曱基-3-氧代-雄_ι,4-二烯_17/3_羧酸氰基甲 S旨0 最佳者爲: 17α-(2,2-二氣-3,3-二甲基環丙基羰基)氧基·6α,9α_二氟 -11/?-羥基-16α-甲基-3-氧代-雄_ι,4·二烯·π/?-羧酸氰基甲 酯; 6α,9α-二氟-11β-羥基-16α-甲基-3-氧代-17ο;-(2,2,3,3·四 曱基環丙基羰基)氧基-雄-1,4-二烯-17/3-羥硫代酸S-氰基甲 酯;及 6α,9α-二氟-11/3-羥基-16α-甲基-3-氡代- ΐ7α-(2,2,3,3-四 曱基環丙基羰基)氧基-雄-1,4-二烯-17/3-羧酸氰基曱酯。 最佳者爲 6α,9α-二氟-11/3-羥基-16α-甲基-3-氡代 _Πα-(2,2,3,3-四 甲基環丙基幾基)氡基-雄-1,4-二烯-1 7]8-緩酸氰基甲g旨。 式(I)之化合物藉由例如與類糖皮質素受體結合及經由受 體之不正確反應之能力證明具有可能有利之消炎或抗—過 94506.doc •12· 1338694 敏作用,尤其是局部投藥時。因此,式(1)之化合物可能可 用於治療發炎及/或過敏性失調。 可利用本發明化合物之病症實例包含皮膚疾病如濕疹、 牛皮癬、過敏性皮膚炎、神經性皮膚炎、搔癢症及過敏性 反應;鼻子、喉嚨或肺部之發炎症狀,如氣喘(包含過敏引 發之氣喘反應)' 鼻炎(包含熱病)、鼻内息肉、慢性阻塞性 肺部疾病、空胞肺部疾病及纖維變性;發炎性腸症狀如潰 癌性結腸炎及孔蘿氏病;及自我免疫性疾病如風濕性關節 炎。 本發明化合物亦具有治療結腸及結膜炎之用途。 熟習本技藝者應瞭解本文所指之治療爲預防以及治療已 經發生之症狀。 如上述,式(I)之化合物可用於人類或獸醫用醫藥,尤其 是消炎及抗過敏劑。 因此本發明另一目的爲人類或獸醫用醫藥中所用之式⑴ 化合物或其生理上可接受之溶劑化物,尤其是治療發炎及/ 或過敏性症狀之病患。 本發明另一目的係提供式(I)化合物或其生理上可接受之 溶劑化物在製造治療發炎及/或過敏症狀之病患之醫藥上 之應用。 本發明另一或其他目的係提供一種治療發炎及/或過敏 症狀之人類或動物標的之方法’該方法包括對該人類或動 物標的投予有效量之式⑴化合物或其生理上可接受之溶劑 化物。 94506.doc -13- 1338694 ,且本 可接受 之稀釋 本發明化合物可針對依任何方便之方式投藥調配 叙明之乾圍因此亦包含包括式⑴化合物《其生理上 之溶劑化物,且若需要 劑或載劑混合。 可與一或多種醫藥可接受 另外’本發明提供"種製備該醫藥組合物之方法,包括 使諸成分混合。 本發明化合物可爲例如經調配供口服、頰内、舌下、非 經腸胃、局部或直腸投藥,尤其是局部投藥。 本發明所用之局部投藥包含以吹氣或吸人投藥。局部投 藥之各類製劑實例包含軟膏、乳液、乳霜、凝膠、發泡體, 以經皮貼片輸送之製劑’吸人或吹氣用之粉末、噴霧劑、 氣♦膠、膠囊或藥匣’或滴劑(例如眼晴用或鼻子用滴劑), 供霧化用溶液/懸浮液、拴劑、陰㈣检、駐留灌腸劑及吸 嚼劑或可吸入之鍵劑戎藥Μ <办丨,、A # > Α 一 狄w a樂月(例如治療咬潰瘍性潰瘍)或脂 質或爲膠囊製劑。 軟膏、乳雙及凝膠可例如配合水性或油性基質,且添加 適用增稠劑及/或膠凝劑及/或溶劑調配。該基質因此可包含 例如水及/或油,如液態鏈烷或植物油,如花生油或萬麻 油,或溶劑如聚乙二醇。可依據基質性質使用之增稠劑及 膠凝劑包含軟質鏈烷、硬脂酸鋁、鯨醯硬脂基醇、聚乙二 醇、毛脂肪、蜜蠟、羧基聚亞甲基及纖維素衍生物,及/或 單硬脂酸甘油酯’及/或非離子性乳化劑。 乳液可配合水性或油性基質調配,且通常亦含有一或多 種乳化劑、安定劑、分散劑'懸浮劑或增稠劑。 94506.doc 外塗用粉末可配合任何適用之粉末狀基質形成,例如滑 石、乳糖或澱粉。滴劑可配合水性或非水性基質調配,且 亦包括一或多種分散劑、溶解劑、懸浮劑或保存劑。 噴霧組合物可例如調配成水溶液或懸浮液,或調配成自 預加壓仫輸送之氣溶膠,如劑量吸入器,且配合使用適用 之液化推進劑。適用於吸入用之氣溶膠組合物可爲懸浮液 或溶液’且通常含有式⑴化合物及適用之推進劑如敦碳化 物或含氫之氣氟碳化物或其混合物,特別是氫氟烷,尤其 疋u,i,2-四氟乙烷' 七氟正丙烷或其混合 物。該氣溶膠組合物可視情況含有額外之技藝中習知之調 配佐藥,如界面活性劑例如油酸或卵磷脂及共溶劑例如乙 醇。 較好,本發明調配物可藉由添加適用之緩衝劑緩衝。 吸入或吹氣用膠囊或藥匣可經調配成含有本發明化合物 之供吸入用粉末狀混合物及適用之粉末狀基質如乳糖或澱 粉。各膠囊或藥匣一般可含20微克-10毫克之式⑴化合物。 或者’本發明化合物可在沒有佐藥如乳糖下存在。 本發明局部用組合物中式(I)活性化合物之比例端賴欲製 備调配物之確切類型而定,但一般均在〇·〇〇 1至1 〇 wt%之 間。然而針對大部分之製劑類型,通常較佳之使用比例為 0.005至1% ’且較好為〇.〇1至0.5%。然而,對於吸入或吹氣 用粉末,所用之比例在0.1至5%之間。 氣溶膠調配物較好經安排使得氣溶膠之各計量劑量或 "puff”含有20微克-2000微克。較好約20微克_500微克間之 94506.doc 式(I)化合物。投藥可每日一次或每日數次,例如2、3、^ 或8次,且每次可例如1、2或3劑量。氣溶膠之全天劑量可 在1〇〇微克-10毫克之間,且較好在2〇微克_2〇〇〇微克之間。 吸入及吹氣用之以膠囊及藥匣輸送之全天劑量及計量劑量 一般為氣溶膠調配物之兩倍。 局部用製劑可藉由每天對欲作用之區域施用一或多次投 藥;且在皮膚區域上較好使用覆蓋貼片。可藉由黏著劑儲 存系統持續或延長輸送。 針對體内投藥,本發明化合物可例如以慣用方式,針對 口服、非經腸胃或直腸投藥調配。口服投藥用調配物包含 糖聚、甘草劑、粉末、細顆粒、旋劑及勝囊,此等一般均 含有慣用之適當佐藥如結合劑、填充劑、潤滑劑、崩解劑' 潤濕劑、m浮劑、乳化劑、保存劑、缓衝用鹽、調味劑、 調色劑及/或增填劑。然而單位劑型較好如下述。 體内投藥用較佳劑型為劑量單位型式,亦即錠劑及膠 囊-亥單位劑型含01毫克至2〇毫纟,較好2 5至⑽克之本 發明化合物。 本發明化合物-般在顯示需全身表皮治療之情況下,可 藉由體内投藥給予。 斤稱之内臟投藥用製劑可依所含製劑之種類含㈣5 變,°活性成分。每日劑量可自G.1毫克至60毫克,例如5-30 毫克依奴冶療之症狀及所需治療期間而定。 較佳者為緩慢釋出或腸内包衣之調配物,尤其是針對發 炎性腸疾病之治療。 94506.doc 1338694 本發明之化合物及醫藥調配物可與一或多種其他治療劑 併用或包含該等治療劑,例如選自消炎劑、反副交感神經 作用劑(尤其是1^/^[2/]^3受體拮抗劑;),β2_腎上腺素受體促 效劑、抗感染劑(例如抗生素、抗過性病原體))、或抗組織 胺。本發明另依目的因此提供包括式(1)化合物或其醫藥可 接受性鹽、溶劑化物或其生理功能衍生物,與一或多種其 他治療用活性劑一起之結合劑,例如選自消炎劑(例如另一 種類糖皮質素或NS AID)、反副交感神經劑、β2_腎上腺素受 體促效劑、抗感染劑(例如抗生素、抗過性病原體或抗 組織胺。較佳之結合物包括式(I)化合物或其醫藥可接受性 鹽、、/谷劑化物或其生理功能衍生物以及β2 _腎上腺素受體促 效劑及/或反副交感神經劑 '及/或PDE-4抑制劑。較佳之結 合物為包括一或二種其他治療劑者。 熟習本技藝者清楚較好其他治療成分可以鹽形式(例如 鹼金屬或胺鹽或酸加成鹽)、或前藥或酯(例如低級烷酯)或 溶劑化物(例如水合物)使用,使治療成分之活性及/或安定 性及/或物理特徵(例如溶解度)為最佳。其亦了解較好治療 成分可以光學上純的形式使用。 較佳者為包括本發明化合物與β2-腎上腺素受體促效劑 一起之結合劑。 β2_腎上腺素受體促效劑之實例包含沙美特醇 (salmeterol)(例如消旋體或單一對映體如R-對映體)、沙必坦 醇(salbutamol)、服莫特醇(formoterol)、沙美非醇 (salmefamol)、非諾特醇(fenoterol)或特必特林(terbutaline) 9450C.doc •17· 及其鹽,例如沙美特醇之希納服酸(xinafoate)鹽 '沙必坦醇 之硫酸鹽或游離鹼或服莫特醇之富馬酸鹽。較佳者為長效 性β2-腎上腺素受體促效劑,尤其是治療作用超過24小時 者,如沙美特醇或服莫特醇。較佳者長效β2_腎上腺素受體 促效劑包含 W0 02/066422、W0 02/070490、W0 02/076933 ' W0 03/024439、W0 03/072539、WO 03/091204、W0 04/016578、 W0 2004/022547、W0 2004/037807、WO 2004/037773、W0 2004/037768 ' WO 2004/039762 ' WO 2004/039766 > WO 01/42193 及W0 03/042160所述者。 最佳之長效性β2-腎上腺素受體促效劑包含下式(XX)之 化合物或其鹽或溶劑化物:
m為2至8之整數; η為3至11之整數; 其條件為m+n為5至1 9, R21 為-XS02NR26R27,其中 X為-(CH2)P或 C2.6伸烷基; R26及R27獨立選自氫、Cu烷基、C3.7環烷基、C(0)NR28R29、 苯基及笨基(CU4烷基)-, 或R2(S及R27與其所鍵結之氮一起形成5-、6-或7-員含氮之 環,且R26及R27各視情況以一或二個選自鹵基、Cu6烷基、 94506.doc • 18- .338694
Ci-6齒燒基、Ci_6烷氧基、羥基取代之c16烷氧基、_c〇2r28、 · -S02NR28R“、c〇nr28r29、_nr28c(〇)r29、或5、6_或7_ , 員雜環狀環; R28及R29係獨立選自氫、Ci 4烷基、Cw環烷基、苯基及笨 基(Ci.4烧基)-;且 p為0至6 ’較好為〇至4之整數; R22及R23係獨立選自氫、C|_6烷基、C〗6烷氧基、鹵基、笨 基及烧基;且 R24及R25係獨立選自氳及CN4烷基,其條件為r2ir25中之 總碳原子數不超過4個。 最佳之長效型β2·腎上腺素受體促效劑如下: 3-(4-{[6-({(211)-2-羥基-2-[4-羥基-3-(羥基甲基)笨基]乙 基}胺基)己基]氧基} 丁基)苯磺醯胺; 3- (3-{[7-({(2R)-2-羥基-2-[4-羥基-3-(羥基甲基)苯基]乙 基}胺基)己基]氧基}丙基)苯磺醯胺; 4- {(111)-2-[(6-{2-[(2,6-二氣苯基)氧基]乙氧基}己基)胺 基]-1_羥基乙基}-2-(羥基曱基)酚; 4- {(lR)-2-[(6- {4-[3-(環戊基績酿基)苯基]丁氧基}己基) 胺基]-1-羥基乙基丨-2-(羥基曱基)酚; N-[2-羥基-5-[(lR)-l-羥基-2-[[2-4-[[(2R)-2-羥基-2-苯基 乙基]胺基]苯基]乙基]胺基]乙基]苯基]曱醢胺;及 N-2{ 2-[4-(3-苯基-4-甲氧基苯基)胺基苯基]乙基卜2_經基 -2-(8-羥基-2(1H)-喳啉-5-基)乙胺。 適用之消炎劑包含類糖皮質素。可與本發明化合物併用 94506.doc -19· 之適用反副交感神經作用劑為具有消炎活性之口服及吸入 用類糖皮質素及其前藥。實例包含甲基去氫撥尼松(methyl prednisolone)、去氫撥尼松(prednis〇1〇ne)、地塞米松 (dexamethasone)、伏替卡松丙酸鹽(fjuticasone propionate)、 6α,9ο:-二氟-11/3-經基-16α-甲基- ΐ7α-[(4-甲基- l,3-p塞口坐-5-羰基)-3-氧代-雄-1,4-二烯-17/3-羧酸s-氟甲酯,6α,9α-二氟 -17ο;-[(2-呋喃基羰基)氧基]-11心羥基_16α_甲基_3_氧代-雄 -1,4-二烯-17/3-羥硫代酸S-氟甲酯,6α,9α-二氟-11|3-羥基 -16α-曱基-3-氧代-17α-丙醯基氧基-雄4,4_二烯-17/3-羥硫 代kS-(2-氧代-四虱吱喃_3S-基)g旨,貝克羅美色松 (beclomethasone)酯(例如17-丙酸酯或17,21-二丙酸酯),必 第松奈(budesonide)、服尼索萊(fiunisolide)、莫美塔松 (mometasone)酯(例如糠酸酯;)、三美西諾酮乙醯替 (triamcinolone acetonide)、羅非彭替(rofleponide)、西里所 替(ciclesonide)(16〇f’17-[[(R)-環己基亞甲基]雙(氧 基)]-11 沒,21-二羥基-pregna-l,4-二婦-3,20-二酮),必替所克 丙酸鹽(butixocort propionate), RPR-106541,及 ST-126。較佳 之類糖皮質素包含吱替卡松(fluticasone)丙酸醋、6α,9α-二 氟-11/3-羥基-16α-甲基-17α-[(4-甲基-1,3-嘍唑-5-羰基)-3-氧 代-雄-1,4-二烯-17沒-羧酸S-氟甲酯,及6α,9〇!-二氟-17q:-[(2-呋喃基羰基)氧基]-11/3-羥基·16α-曱基-3-氧代-雄-1,4-二烯 -17/5-羥硫代酸s-氟曱酯’最佳者為6α,9α-二氟_ΐ7α-[(2-呋。南 基羰基)氧基]-11卜羥基-16α-曱基-3-氧代-雄-1,4-二烯-17/3» 羥硫代酸S-氟甲酯。 94506.doc -20- 1338694 具有類糖皮質素促效之非類固醇化合物可能具有優於反 -活化作用之反壓抑作用選擇性,且可用於合併療法,包含 以下專利中所涵蓋者:WO03/082827、W001/10143、 W098/54159、W004/005229、W004/009016、W004/009017、 W004/018429、W003/104195、WO03/082787、W003/082280、 WO03/059899、W003/101932、W002/02565、WO01/16128、 WO00/66590、WO03/086294、WO04/026248、W003/061651、 W003/08277。
適當之消炎劑包含非類固醇消炎藥物(NSAID's)。
適用之NSAID's包含色甘酸鈉、尼朵克羅米(nedocromil) 鈉、磷醯二酯酶(PDE)抑制劑(例如茶鹼、PDE4抑制劑或混 合之PDE3/PDE4抑制劑)、白三稀括抗劑、白三稀合成之抑 制劑(例如,蒙塔盧卡斯特(montelukast))、iNOS抑制劑、色 胺酶及彈性酶抑制劑、β-2因塔林(integrin)拮抗劑及腺甞酸 受體促效劑或拮抗劑(例如腺甘酸2a促效劑)、細胞素拮抗劑 (例如,化學激素拮抗劑,如CCR3拮抗劑)或細胞素合成之 抑制劑,或5-脂質氧酶抑制劑。適用之其他β2-腎上腺素受 體促效劑包含沙美特醇(例如希納服酸鹽(xinafoate))、沙必 坦醇(salbutamol)(例如硫酸鹽或游離驗)、服莫特醇 (formoterol)(例如富馬酸鹽);非諾特醇(fenoterol)或特必塔 林(terbutaline)及其鹽。iNOS(包含硝酸氧化物抑制劑)較好 供口服投藥。適用之iNOS抑制劑包含揭示於W093/13〇55、 WO98/30537、W002/50021、W095/34534及 W099/62875 中 者。適用之CCR3抑制劑包含WO02/26722中揭示者。 94506.doc 特別受矚目者為式⑴化合物與磷醯二酯酶4(PDE4)抑制 劑併用’尤其是適用於吸入之調配物。本發明目標中所用 之PDE4-標定之抑制劑可為已知用於抑制PDE4酵素之任一 化合物’或發現可用作PDE4抑制劑者,且其僅為PDE4抑制 劑’非為抑制PDE族群之其他組份如PDE3及PDE5以及 PDE4。 受矚目之化合物包含 順式-4-氰基-4-(3-環戊基氧基-4-甲氧基苯基)環己烷-1-繞酸’ 2-碳曱氧基_4_氰基-4-(3-環丙基甲氧基-4-二氟甲氧 基笨基)環己烷-1-酮及順式-[4-氰基-4-(3-環丙基甲氧基-4-二氟曱氧基苯基)環己烷-1 -醇]。以及,順式_[4_氰基 _4-[3-(環戊基氧基)_4_曱氧基苯基]環己烷_丨_羧酸(亦已知 為西羅米雷斯特(cilomilast))及其鹽 '酯、前藥或物理形式, 其係敘述於1996年9月03號頒授之美國專利第5,552,438號 中’該專利及其揭示之化合物均併入本文中供參考。
Elbion 之 AWD-12-281(Hofgen,N.等人,15th EFMC Int Symp Med Chem (Sept 6-10, Edinburgh) 1998, Abst P.98; CAS reference No. 247584020-9); -種NCS-613 (INSERM) 命名之 9-芊基打因(9-benzyladenine)衍生物;Chiroscience 及 Schering-Plough 之 D-4418; —種由 ci-1018 (PD-168787) 確認且歸輝瑞藥廠所有之苯并二吖庚因PDE4抑制劑;由 Kyowa Hakko於W099/16766中揭示之笨并二吟茂烷衍生 物;來自 Kyowa Hakko 之 K-34 ;來自 Napp 之 V-11294A (Landells, L.J.專人,Eur Resp J [Annu Cong Eur Resp Soc 94506.doc •22- P38694 (Sept 19-23, Geneva) 1998] 1998, 12 (Suppl. 28): Abst , P2393);羅福米雷斯特(roflumilast)(CAS 參考編號No 162401-32-3)及 Byk-Gulden 之塞拉西松(pthalazinone) (W099/47505,該揭示併入本文中供參考);普嗎飛汀 (Pumafentrine),(-)-p-[(4aR*,10bS*)-9-乙氧基-l,2,3,4,4a,10b-六 氫-8-曱氧基-2-曱基苯并[c][l,6]莕啶-6-基]-N,N-二異丙基 苯醯胺;其係與已經製備之PDE3/PDE4抑制劑混合,且由 Byk-Gulden公佈;如今,Altana ;由 Almirall-Prodesfarma 發展之阿諾非林(31'〇『丫11丨116);\^1>1131丨5之\^]\4554/11]^5 65;或 T-440(Tanabe Seiyaku; Fuji, K.等人· J Pharmacol Exp Ther,1998, 284(1): 162)及 T2585。 受矚目之另一化合物係揭示於公告之國際專利申請案 WO04/024728 (Glaxo Group Ltd) ' PCT/EP2003/014867 (Glaxo Group Ltd)及 PCT/EP2004/005494 (Glaxo Group Ltd)中。 適用之反副交感神經作用劑為在毒菌鹼受體處作為拮抗 劑之該等化合物,尤其是…或!^^受體之拮抗劑,Μ丨/M3或 M2/M3受體之雙拮抗劑,或Μ,/Μζ/Ν^受體之pan-拮抗劑。經 吸入投藥之類舉化合物包含伊帕妥(ipratropium)(例如溴化 物,CAS 22254-24-6,以Atrovent之名稱銷售),歐希妥 (oxitropium)(例如溴化物,CAS 30286-75-0)及替歐妥 (tiotropium)(例如,漠化物,CAS 136310-93-5,以Spiriva 之名稱銷售)。亦受矚目者為李凡托配(revatropate)(例如, 氫溴化物,CAS 262586-79-8)及LAS-34273,其係揭示於 WOO 1 /04118中。供口服投藥列舉之化合物包含否蘭庚因 94506.doc -23- 1338694 (pirenzepine)(CAS 28797-61-7) ’ 達里非納新(darifenacin)(CAS 133099-04-4或CAS 13 3099-07-7,針對氩溴化物,以 Enablex 之名稱銷售),氧基必替尼(oxybutynin)(CAS 5633-20-5,以 Ditropan之名稱銷售),妥羅第林(terodiline)(CAS 15793-40-5) ’ 拓特羅啶(tolterodine)(CAS 124937-51-5或CAS 124937-52-6,針 對酒石酸鹽,以Detrol之名稱銷售),歐替羅林(otilonium)(例 如漠化物,CAS 26095-59-0,以Spasmomen之名稱銷售), 妥斯拼氣化物(trospium chloride)(CAS 10405-02-4)及所立菲納 新(solifenacin)(CAS 242478-37-1 或 CAS 242478-38-2,針對 丁二酸鹽,亦已知為YM-905且以Vesicare之名稱銷售)。 其他適用之反副交感神經劑包含下式(XXI)之化合物’其 係揭示於美國專利申請案第60/487981號中:
其中附接於托烷環之烷基鏈之較佳定向為橋接; R31及R32係獨立選自由較好具有1至6個碳原子之直鏈或支 鏈低級烷基、具有5至6個碳原子之環烷基、異有6至10個碳 原子之環烧基-烧基、2 - p塞吩基、2 -β比。定基、苯基、以具有 不超過4個碳原子之烷基取代之苯基,及以具有不超過4個 碳原子之烷氧基取代之笨基组成之群組; X·代表與Ν原子之正電荷結合之陰離子。X—可為(但不限)氣 94506.doc •24- 1338694 化物、演化物、碘化物、硫酸鹽、苯磺酸鹽及甲笨磺酸鹽,, 包含例如: (3-橋)-3-(2,2-二-2-嘧吩基乙烯基)_8,8·二甲基_8-偶氮雙 環[3.2.1]辛烷溴化物; (3-橋)-3-(2,2-二苯基乙烯基)_8,8_二甲基_8·偶氮鑌雙環 [3.2 · 1 ]辛燒〉臭化物; (3-橋)-3-(2,2-二苯基乙烯基)_8,8_二甲基-8_偶氮鏽雙環 [3.2.1]辛烷4·曱基苯磺酸鹽; (3-橋)-8,8-二甲基_3-[2-笨基_2_(2_嘧吩基)乙烯基]-8-偶 氮錄雙環[3 ‘ 2.1 ]辛炫漠化物;及/或 (3-橋)-8,8-二曱基_3_[2_笨基·2_(2-η比啶基)乙烯基]_8-偶 氮鎘雙環[3.2.1 ]辛院溴化物。 另一適用之反副交感神經劑包含下式(χχπ)或(χχπι)之 化合物,其均敘述於美國專利申請案第6〇/5η〇〇9號中:
其中: 顯示之Η原子係在褂位置; 合之陰離子。R41可為(但不限) 硫醆鹽、苯磺酸鹽及曱苯磺酸 R41代表與Ν原子之正電荷結合之 氣化物、溴化物、碘化物、硫醆 鹽, 94506.doc -25· x^38694 R及R係獨立選自由直鏈或支鏈低級烷基(較好具有1至6 個碳原子)、環烷基(具有5至6個碳原子)、環烷基-烷基(具 有6至1〇個碳原子)、雜環烷基(具有5至6個碳原子,且以N 或0作為雜原子)、雜環烷基-烷基(具有6至10個碳原子,且 以N或〇作為雜原子)、芳基、視情況取代之芳基、雜芳基及 視情況取代之雜芳基組成之群組; R44係選自由下列組成之群組:(Ci ό)烷基、(c3 12)環烷基、 (c3-7)雜環烧基、(Cl 6)烷基& 12)環烷基、(Ci 6)烷基& 7) 雜環烷基、芳基、雜芳基、(Ci j烷基_芳基、(Ci 6)烷基雜 芳基、-OR45、-CH2OR45、-CH2OH、-CN、-CF3、-CH20(C0)R46、 -C02R47、-CH2NH2、-ch2n(r47)so2r45、-S02N(R47)(R48)、 -CON(R47)(R48), -CH2N(R48)CO(R46)' -CH2N(R48)S02(R46) 、-CH2N(R48)C〇2(R45)、·ςΗ2Ν(Ι148)(:ΟΝΗ(Ι147); R45係選自由下列組成之群組:(Ci 6)烷基、(Ci 6)烷基(C3 η) 環烷基、(c,,6)烷基(c:3·7)雜環烷基、(Ci 6)烷基_芳基、(Ci 6) 烷基雜芳基; R46係選自由下列選自之群組:(Ci 6)烷基、(c3 i2)環烷基、 (c3-7)雜環烷基、(Cl 6)烷基(C3 i2)環烷基、(Ci 6)烷基(C3 7) 雜環烷基、芳基、雜芳基、(Ci 6)烷基_芳基、(Ci 6)烷基_雜 方基; R47及R48係獨立選自由下列組成之群組:H、(Ci_6)烷基、 (c3-l2)環烷基、(c3-7)雜環烷基、(Ci 6)烷基(C3 i2)環烷基、 (C!-6)院基(C3_7)雜環烷基、(Ci6)烷基_芳基及& 6)烷基_雜 务基;包含例如: 94506.doc 1338694 (橋)-3-(2 -曱氧基-2,2-二硫代苯-2-基乙基)-8,8-二甲基-8-偶氮鑌雙環[3.2.1]辛烷碘化物; 3-((橋)-8-曱基-8-氮雜-雙環[3.2.1]辛-3-基)-2,2-二苯基- 丙腈; (橋)-8-甲基-3-(2,2,2-三苯基-乙基)-8-氮雜-雙環[3.2.1]辛 烷; 3-((橋)-8-曱基-8-氮雜-雙環[3.2.1]辛-3-基)-2,2-二苯基-丙醯胺; 3-((橋)-8-甲基-8-氮雜-雙環[3.2.1]辛-3-基)-2,2-二笨基-丙酸; (橋)-3-(2-氰基-2,2-二苯基-乙基)-8,8-二曱基-8-偶氮鑕-雙環[3.2.1]辛烷碘化物; (橋)-3-(2-氰基-2,2-二苯基-乙基)-8,8-二甲基-8-偶氮鑕-雙環[3.2.1]辛烷溴化物; 3-((橋)-8-甲基-8-氮雜-雙環[3.2.1]辛-3-基)-2,2-二苯基-丙-1 -醇; N-芊基-3-((橋)-8-曱基-8-氮雜-雙環[3.2.1]辛-3-基)-2,2-二苯基-丙醯胺; (橋)-3-(2-胺基甲醯基-2,2-二苯基-乙基)-8,8-二甲基-8-偶 氮鑌-雙環[3.2.1]辛烷碘化物; 1-芊基-3-[3-((橋)-8-甲基-8-氮雜-雙環[3.2.1]辛-3-基)-2,2-二苯基-丙基]-尿素; 1-乙基-3-[3-((橋)-8-甲基-8-氮雜-雙環[3.2.1]辛-3-基)-2,2-二苯基-丙基]-尿素; 94506.doc -27- Ϊ338694 基 N-[3-((橋)-8-曱基-8·氮雜-雙環[3 21]辛·3_基)_2,2_二笨 •丙基]-乙醯胺; N-[H(橋)-8-甲基-8-氣雜-雙環[3.2辛_3_基)_2,2•二笨 基-丙基]-苄醯胺; 3-((橋)-8-曱基-8-氮雜-雙環⑶叫辛+幻仏二硫代 苯·2-基-丙腈; (橋)-3-(2-氰基-2,2-二-硫代苯_2-基_乙基)·88二甲基·8_ 偶氮鑌-雙環[3.2.1]辛烷碘化物; &
N-[3-((橋)-8-甲基-8-氮雜-雙環[3·2…辛^•基)2 2二苯 基-丙基]-苯橫酿胺; [3-((橋)-8-甲基-8-氮雜-雙環[3.2.1]辛_3_基)_2 2二苯其 丙基]-尿素; N-[3-((橋)-8-甲基-8_氮雜-雙環[3.21]辛_3_基)2,2·二苯 基-丙基]-曱烷磺醯胺;及/或 (橋)-3卞,2-二苯基苯基-甲醯基)_胺基]_丙 基}-8,8-二甲基-8-偶氮鑕-雙環[3.2.1]辛烷漠·化物。 本發明中所用最佳化合物包含: (橋)-3-(2-甲氧基-2,2-二-硫代苯-2-基-乙基)_8,8_二甲基 -8-偶氮鏆雙環[3.2.1]辛烷碘化物; (橋)-3-(2-氰基-2,2-二苯基-乙基)-8,8-二甲基_8_偶氮鏆_ 雙環[3.2.1]辛烷碘化物; (橋)-3-(2-氛基-2,2-二苯基-乙基)-8,8-二甲基_8_偶氮鏘_ 雙環[3.2.1 ]辛烧溴化物; (橋)-3-(2-胺基甲醯基_2,2_二苯基-乙基)_8,8_二甲基_8_偶 94506.doc -28 - 1338694 氮鑌-雙環[3.2.1]辛烷碘化物; (橋)-3-(2-氰基-2,2-二硫代苯-2-基-乙基)-8,8-二甲基-8-偶氮鑌-雙環[3.2.1]辛烷碘化物;及/或 (橋)-3-{2,2-二苯基-3-[(l-苯基-曱醯基)-胺基]-丙 基}-8,8-二曱基-8-偶氮鑌-雙環[3.2.1]辛烷溴化物。 適用之抗組織胺(亦稱之為H1-受體拮抗劑)包含可抑制 H1-受體且對於人類之應用安全之任一或多種已知之拮抗 劑。第一代拮抗劑包含乙醇胺之衍生物、乙二胺及烷基胺, 例如二苯基醇胺、比里胺(pyrilamine)、克里美斯汀 (clemastine)、氯吩里胺(chloropheniramine)。第二代拮抗劑(非 鎮靜)包含羅雷替定(loratidine)、第羅雷替定(desloratidine)、 特非納定(terfenadine)、斯特米吐(astemizole)、阿里凡斯汀 (acrivastine)、阿雷斯汀(azelastine)、雷佛希替井(levocetirizine)、 非諾非納 °定(fexofenadine)及希替井(cetirizine) 0 較佳抗組織胺之實例羅雷替啶(l〇ratidine)、第羅雷替啶 (desloratidine)、非諾非納啶(fexofenadine)及希替井(cetirizine)。 本發明另一目的因此提供一種包括式⑴化合物或其醫藥 可接受性鹽、溶劑化物或其生理功能衍生物與ΡΙ)Ε4抑制劑 一起之結合物。 本發明另一目的因此提供一種包括式(I)化合物或其醫藥 可接文性鹽、溶劑化物或其生理功能衍生物與β2_腎上腺素 受體促效劑一起之結合物。 本發明另一目的因此提供一種包括式(I)化合物或其醫藥 可接欠性鹽、溶劑化物或其生理功能衍生物與反副交感神 94506.doc -29- Π38694 經劑一起之結合物。 本發明另一目的因此提供一種包括式(I)化合物或其醫藥 又丨生谷劑化物或其生理功能衍生物與抗組織胺一 起之結合物。 本發明另一目的因此提供一種包括式⑴化合物或其醫藥 可接$性鹽、溶劑化物或其生理功能^生物與pDE_4抑制劑 及β2·腎上腺素受體促效劑一起之結合物。 本發明另-目的因此提供一種包括式⑴化合物或其醫藥
可接受性鹽、溶劑化物或其生理功能衍生物與反副交感神 經劑及PDE-4抑制劑一起之結合物。 上述結合物一般可以醫藥調配物之形式使用,且因此本 發月另目的為包括上述定義之結合物與醫藥可 釋劑或載劑-起之醫藥調配物。 稀
5物之單獨化合物可依序或分開同時或合併之醫 s周配物投樂。較好,兮社入从^ TO ^ 好及、纟°合物之單獨化合物可以合併之 藥調調配物同時投華。p 4 Λ
于奴樂已知冶療劑之適當劑量為熟習苯 藝者所習知。 式⑴化合物及其溶劑化物可藉由以下所述方法製備,且 構成本發明另一目的。 表1有且 製備式⑴化合物之本發明方法包括下式(11)之緩 或羥硫代酸(X = s) 94506.doc •30· 1338694
0、\ /XH
X及=-均如之前之定義
其中 R,、R2、r3、R 與式L-CH^CN(其中L代表離去基)之化合物反應。 依該方法’式(11)之化合物可與式L-CH2-CN(其中L代表離 去基如li素原子或甲苯磺酸基或甲烷磺酸基等)在標準條 件下反應。例如,該反應可在惰性極性溶劑例如N,N二甲 基甲醯胺中’且在驗如碳酸針、碳酸氫鈉存在下進行。 式(II)之化合物一般可以鹽(當該鹽可以結晶態或以溶劑 化物製備時)使用。 式L-CH^CN之化合物為已知或可以已知之方法製備。 式(II)之化合物可由下式(Ιπ)之相對應17α -羥基衍生物:
其中R2、R3、R4、X及=岣如之前定義, 9450C.doc '31 - 使用例如G. H. PMllipps等人’醫藥化學期刊(J〇urnal 〇f
Medicinal Chemistry), (1994),37, 3717-3729所述之方法製 備。該步驟一般包括在溫和之驗例如三乙胺存在下,添加 適用於進行酯化作用之試劑於酯中,如式R/ΟΟΗ之化合物 或其活化之衍生物例如活化酯、其酸酐或其鹵化物,尤其 是酸性鹵化物。咪唑酯在該反應中可提供酸性氣化物另依 方便之選擇。例如’ 1,2-二甲基-1H-咪唑酯(IV)代表2,2,3,3,- 四甲基環丙烷羧酸之一般結晶活化衍生物。
一般酸性氣化物或其他活化羧酸衍生物相對於式(ΙΠ)之 化合物可以至少2倍之莫耳量使用。第二莫爾之酸性氯化物 會與式(III)化合物中之羧酸/羥硫代酸基團反應,且必須藉 由與胺如二乙胺或1-甲基哌畊反應移除。 本發明另一目的係提供一種製備下式(11)化合物之方法
其中Ri代表2,2,3,3-四甲基環丙基,且r2、R3、R4、X及% 均如上述定義,該方法包括使2,2,3,3_四曱基環丙烷羧醆 94506.doc 1338694 (IV)之1,2-二曱基-1H-咪唑酯: 〇
(IV) 與下式(III)之相對應17α-羥基衍生物反應。
式(in)之化合物為已知或可以G H phUlipps等人,醫藥 化學期刊(Journal 〇f Medicinal Chemistry),(1994),37, 3717-3729所述之程序製備。 以下式(II)化合物為新穎,且構成本發明之目的: Π〇Κ4-[(二乙基胺基)磺醯基]芊醯基)氧基-6α,9α_二氟 •U卜經基·16α_甲基·3·氧代-雄-Μ·二烯-17/5-經硫代酸; 6α,9ο:-一氟-17α-(2,6-二敗爷酿基)氧基]lj3_經基_16α_曱 基-3-氡代-雄-1,4-二烯-ΐ7(3_羧酸; 6〇^’9〇;-一氟-11士技基-17〇;_(4_甲氧基字醯基)氧基_16仏甲 基-3-氡代-雄-1,4-二烯羧酸; ^-(4_氰基字酿基)氧基⑽9…二氣·叫經基物甲基 -3-氡代-雄-1,4-二烯_i7jg_羧酸; ,9α 一氟17α-(3,3-二甲基丁醯旬氧基i尽經基_16α_ 94506.doc ·33· 1338694 曱基-3-氧代-雄-1,4-二烯-17j3-羧酸; , 6α,9α-二氟-11/3-羥基_17义(2-異丙基-1,3-«»塞唑-4-羰基)氧 - 基-16α-曱基-3-氧代-雄-1,4-二稀-17/3-緩酸; 6α,9α-二氟-Ilf羥基-16α-甲基-3-氧代-17α-〇奎啉-2-羰 基)氧基-雄-1,4-二烯-17/3-羧酸; 6α,9α-二氟-11/3-羥基-16α-甲基-3-氧代-17α-(5-三氟甲基 夫喃-2-叛基)氧基-雄-1,4-二稀-17/3-敌酸; 6〇ί,9〇ί- 一氣-11/J-經基-16(¾-甲基-17ο;-(5 -甲基績酿基-ρ塞吩 -2-羰基)-3-氧代-雄-1,4-二烯-17/5-羧酸; 6α,9α-二氟-11/3-羥基-16α-甲基-17α-(5-甲基硫基-嘧吩 -2-羰基)氧基-3·氧代-雄-1,4-二烯-17|8-羧酸; 6〇:,9〇;-二氟-17α-(5-乙基·異嘮唑-3-羰基)氧基-11/?-羥基 -16α-甲基-3·氧代-雄-1,4-二烯-17/3-羧酸; 170:-(5-氣-4-曱氧基-嘧吩-3-羰基)氧基-6〇!,9〇:-二氟-11/3-羥基-16α-甲基-3-氧代-雄-1,4-二烯-17/3-羧酸; 17α-(2,2-二氣-3,3-二曱基環丙基羰基)氧基-6α,9α-二氟 -11卢-經基-16α-甲基-3-氧代-雄-1,4-二稀-17/3-缓酸; 17〇!-(2,2-二氣-3,3-二甲基環丙基羰基)氧基-6〇:,9«-二氟 -11/5-羥基-16α-甲基-3-氧代-雄-1,4-二烯-17/3-羥硫代酸; 6〇ί,9α-二氟-11/5-羥基-16ο;-甲基-ΐ7α-(5-曱基磺醯基-嘍吩 -2-羰基)氧基-3-氧代-雄-1,4-二烯-17/3-羥硫代酸; 6α,9α-二氟-U/3_羥基-16α-甲基·3-氡代-17〇!-(5·三氟曱基 -吱喃-2-羰基)氧基··雄-1,4-二烯-17/?-羥硫代酸;及 6α,9α-二氟·ι7ίχ·(3·(二氟曱基硫基)芊醯基)氧基-11/3_羥 94506.doc •34- 1338694 基-16α-曱基-3·氡代·雄_丨,4_二烯_17心羥硫代酸。 式(Iv)之化合物’ 3_二甲基·w(2,2,3,3·四甲基環丙基)鼓 基]-1H-咪唑-3-鑌氣化物為且構成本發明之目的。
式㈣之化合物亦可藉由包括以下步驟之方法製備:
獲付竣酸(III 步驟(a)包括使含式(V)化合物之溶液氧化 x=0); 較好,步驟⑷係在包括甲醇、水、四氣咬。南、二号貌或 二乙二醇二甲基趟之溶财進行H為提升產率且座 量,較佳之溶劑為甲醇、水或四氫吱喃,…之溶劑為 水或四氫Μ,尤其是使用水及四氫以作為溶劑。二4 烧及二乙二醇二甲㈣亦為較佳溶劑,其可視情況(且較 與卜起使用。較好,溶劑之用量相對於起始物質(1 ^罝為3至1()體積,更好為4至6體積,最好為5體積。較好 =丨之含量相對於起始物質之量為1,耳當量。例如, 田便用50% w/w過換酸水溶液時,氧 物質—為,.⑴一更二:含量相對於起始 舻 .至3 wt ’更好為丨3 wt。 二’4:步驟將包括使用化學氧化劑。更好,氧化劑為 == 其鹽。最好,氧化劑為過_或過埃酸納, 最子為過碟酸。或者(或另外),亦應了解氧化步驟可包括適 94506.doc -35- 1338694 當之氧化反應’例如使用空氣及/或氧氣者。當氧化反應使 用空氣及/或氧氣時’該反應中所用之溶劑較好為甲醇。較 好’步驟⑷將包含在室溫或稱溫熱,亦即約25t下培養試 片I 2 J時式(111,X=0)之化合物可藉由添加非溶劑自反應 混合物再結晶分離。式(1„,χ=〇)化合物之適用非溶劑為 夂〜外的發現極需要控制在添加非溶劑例如水使式(η/, Χ=〇)之化合物沉澱之條件。當使用冷卻水(例如在0_5t:下 之水/冰混合物)進行再結晶時’雖然可期望較佳之非溶劑性 質,但發現產生之結晶產物及大量,類似軟凝膠,且極不 容易過濾。為不受理論限制,相信該祗密度產物之結晶經 格中含有大置之溶劑化物之溶劑。相反的當所用之條件約 為丨〇°c或更高(例如約周圍溫度)時,可產生極易過濾似沙狀 之細粒產物。在此等條件下,一般會在約丨小時後開始結 晶,且通常在數小時(例如2小時)内完成。在不受理論限制 之情況下,相信該細顆粒產物之結晶經格内含少許或沒有 溶劑化物之溶劑。 步驟(b) —般包括在適用之溶劑例如二甲基甲醯胺存在 下,添加適用於將羧酸(III,x=〇)轉化成羥硫代酸(πι,x=s) 之試劑,例如使用亞硫化氫氣體與適用之偶合劑例如羰基 一 D米。坐(CDI)—起使用。 非生理可接受之式⑴化合物之溶劑化物可用作中間物, 以製備式(I)之化合物或其生理上可接受之溶劑化物。 式⑴化合物及/或其鹽或溶劑化物證明可在類糖皮質素 受體處促效。 94506.doc •36· 1338694 式(i)化合物及/或其鹽或溶劑化物可以可預測之醫藥動· 態及醫藥動力行為證明具有良好之消炎性質。其藉由例如 類糖皮吳素受體優於孕酮黃體激素受體之增加選擇性,及/ 或類糖皮質素受體調節之反抑制優於反活化之增加選擇性 證明,亦具有引人注目之副作用圖像,且似乎可與治療人 類病患之一般攝取相容。 以下非限制用實例說明本發明。 實例 通用實例 層析純化係使用講自Varian之預充填Bond Eluts夕膠盒進 行’或藉由在預充填之Biotage矽膠管柱上以快速層析進 行。該盒在使用前以二氣甲烷預處理。LCMS係在Supelcosil LCABZ+PLUS官柱(3.3公分χ4.6毫米ID)上以含〇 ι% HC02H及0.01 Μ乙酸銨之水(溶劑A),及含0.05% HC02H、 5%水之乙腈(溶劑B),使用以下溶離梯度溶離進行:〇_〇 7 分鐘 0%B,0.7-4.2分鐘 l〇〇%B,4.2-5.3 分鐘 0%B,5.3-5.5 分鐘0%B ’流速為3毫升/分鐘。質譜係使用電噴佈正及負模 型(ES+ve 及 ES-ve),以Fisons VG Platform光譜儀為準記 錄。1HNMR光譜係在BrukerDPX 400光譜儀上,在400.l3 MHz及9.4 Tesla下操作,使用來自7.25 ppm之殘留質子化溶 劑之訊號作為内部標準,以CDC13獲得。 中間物 中間物1 : 6α,9α-二氟-110-羥基-16α-甲基-3-氧代_ΐ7α-(2,2,3,3-四甲基環丙基羰基)氧基-雄-1,4-二烯-17心羥硫代酸 94506.doc -37- 將草酿氣(3毫升,34.9毫莫耳)添加於含有二乙基曱醯胺, (2滴)之含2,2,3,3-四甲基環丙基羧酸(2.48克,17.45毫莫耳) 之無水二氣甲院(70毫升)攪拌且冷卻(冰)溶液中,且使混合 物授掉3小時。蒸發溶劑且將殘留之酸性氣化物在溶解於二 氣甲烷(15毫升)中,且添加於含有三乙胺(2 〇3毫升,丨4 5 毫莫耳)之含6α,9α-二氟-ΐιρ,πα _二羥基_16〇;_甲基_3_氧代 -雄-Μ-二烯 羥硫代酸H PhiUipps等人,(1994)醫 藥化學期刊(Journal of Medicinal Chemistry), 37, 3717-3729)(3 克7·27毫莫耳)之二氣曱院(120毫升)攪拌且冷卻(冰)溶液 中。使混合物升溫至室溫,〗5小時後依序以碳酸氫鈉水溶 液(150毫升)、1 μ鹽酸(150毫升)及食鹽水(丨50毫升)洗滌, 且經親水性玻璃質過濾且蒸發。將殘留之固體溶於二哼烷 (140毫升)中,且添加丨_甲基喊畊(3 23毫升,291毫莫耳), 且使混合物攪拌4小時。再將混合物緩慢添加於含2 Μ鹽酸 (200毫升)及冰(2〇〇毫升)之劇烈攪拌混合物中。混合物以二 氣甲烷(300毫升)萃取,萃取液以水洗滌且經親水性玻璃質 脫水且蒸發。將該物質溶於二„号烷(8〇毫升)中,且再度以卜 甲基吸11 井(3,23毫升)處理20小時。將混合物緩慢添加於含2 μ 鹽酸(200毫升)及冰(2〇〇毫升)之劇烈攪拌混合物中。混合物 以二氣甲烷(300毫升)萃取,萃取液以水洗滌且經親水性玻 璃質脫水且蒸發。在90克biotage盒上先使用環己烷,最後 使用環己烷:乙酸乙酯(3 : 1)層析純化,或得標題化合物 (1.33克):1^1^8駐留時間3.99分鐘。 中間物2: 17α-(Μ(二乙基胺基)磺酿基】苄醯基)氧基_6α 9α_ 94506.doc •38- 1338694 二氟-11心經基-16α甲基-3-氧代-雄-1>4_二稀_17心經硫代酸‘ 將4-[(二乙基胺基)磺醯基]笮醯氯(134毫克)添加於含* 6α,9〇ί-二氟-11/3,17α -二羥基-16α-曱基 _3_ 氧代-雄 _14 二烯 -Π/3-羥硫代酸(200毫克)之吡啶(8毫升)攪拌溶液中,’且使混 合物在氮氣中攪拌2小時。混合物中添加更多酸性氯化物 (134毫克)’再攪拌2小時。接著添加6 M HCi(6〇毫升),且 以乙酸乙酯(3x30毫升)萃取混合物。合併之有機萃取液以 2 M HC1 (3 0毫升)洗滌,經親水性玻璃質脫水且蒸發,獲得 白色發泡狀標題化合物:LCMS駐留時間4.26分鐘。 中間物3 : 17α-(5-氣-4-甲氧基-嘍吩_3·羰基)氧基_6α,9α•二 氟-11/3-羥基-16«-甲基-3-氡代-雄-^·二烯_17心羥硫代酸 使用如中間物2所述類似之方法製備。LCM&^留時間 4 · 0 6分鐘。 中間物4 : 6α,9«-二氟-11心羥基_16α•甲基_3氧代 -17α-(2,2,3,3-四甲基環丙基羰基)氧基―雄^,‘二稀17尽·後酸 使用如中間物1所述類似之方法,自6α,9α_二氟·lljS,17a •二羥基-16α-甲基_3-氧代.雄·ι,4·二烯·17(3_羧酸(G. H Phillipps等人,(1994)醫藥化學期刊(J〇urnal 〇f Medicinal
Chemistry),37, 3717-3729)製備。LCMS駐留時間 3.59分鐘。 中間物5 : 17«-(環己基羰基)氧基_6α,9α_二氟心羥基 -16α-甲基-3-氧代-雄-1,4-二稀-17/3-叛酸 將環己烷碳酿氣(0.081毫升,〇·6毫莫耳)添加於含6α,9α_ 二氟-11沒,17 α -二羥基-16α-甲基_3·氧代-雄_ι,4_二烯_17卜 羧酸(200毫克,0.5毫莫耳)之。比啶(3毫升)攪拌且冰冷(冰) 94506.doc -39- 1338694 溶液中’使混合物㈣2小時’接著倒入2MHm。混合 ㈣乙酸㈣萃取二次’合併之有機萃取液依序以謂如 及食鹽水絲且蒸發,獲得標題化合物(296毫克):lcms 駐留時間3.67分鐘。 中間物6:6«,9«-二氣_17α_(2,6_二氣爷酿基)氧基叫-經基 -16α-甲基-3-氧代-雄-i,4-二烯-17/3羧酸 使用如中間物5所述類似之方法製備。,駐留時間 3.45分鐘。 中間物7··6α,9«·二氟叫·經基_17M4•甲氧基爷酿基)氣基 -16α-甲基-3-氧代-雄_ι,4·二烯_17心绫酸 使用如中間物S所述類似之方法製備。[⑽駐留時間 3.38分鐘。 中間物8 : 170K4-氦基爷酿基)氧基如如二氣吵叛基 -16α-甲基-3-氧代-雄_ι,4·二烯·ι7]8•叛酸 使用如中間物5所述類似之方法製備。_駐留時間 3.36分鐘。 中間物9: 環戊基甲基幾基)氧基二反叫趣基 -16α-甲基-3-氧代-雄“,心二烯_17/3_羧酸 使用如中間物5所述類似之方法製備。⑽駐留時間 3.65分鐘。 中間物: 6«,9«_二氣指-(3,3_二甲基丁醯基)氧基叫· 羥基_16α_甲基·3·氧代-雄-1,4-二烯-17心羧酸 使用如中間物5所述類似之方法製備。⑽駐 3.46分鐘。 $ 94506.doc -40- 1338694 中間物二氣-砂經基-17α·(2_異丙基_13”塞嗤冬. 羰基)氧基-16«-甲基-3-氧代-雄-M_二烯_17尽叛酸 使用如中間物5所述類似之方法製備。LCMS駐留時間· 3.38分鐘。 中間物!2 : 6«,9«-二氟_n㈣基_16〜曱基_3氧代·^如 啉-2·幾基)氧基·雄_Μ_二烯_1η3_幾酸 使用如中間物S所述類似之方法製備。匕⑽駐留時間 3 · 4 6分鐘。 中間物: 6«,9α-二氟叫.經基甲基_3氧代秦& φ 三氟甲基-吱鳴-2_幾基)氧基-雄·li4•二稀·ΐ7心叛酸 使用如中間物5所述類似之方法製備。[⑽駐留時間 3.61分鐘。 -中間物14 : 6α,9«·二氟邻經基-16"基”略甲基續 醜基違吩-2-幾基)-3-氧代·雄-U•二稀_導缓酸 使用如中間物5所述類似之方、土制 只以弋方法製備。iXMSB留時間3 28 分鐘。 中間物15 : 6α,9α-二氟-u心羥基 „ « , Ρ羥基-16〇r-甲基-17α_(5_曱基硫 基塞吩-2-幾基)氧基-3-氧代·雄1 j 乳η雄-1,4-二烯_17/3_羧酸 使用如中間物5所述類似之方 心万忐製備。IXMS駐留時間3.69 分鐘。 乙基-異嘮唑-3-羰基)氡基 ,4_二烯-170-羧酸 中間物 16 : 6α,9α-二氟·17〇{ (s_ -11/3-羥基-16α-甲基-3-氧代^雄】 LCMS駐留時間3.45 使用如中間物5所述類似之方法製備 分鐘。 94506.doc 中間物 17:9C"L_,·甲基·3,氧代-17(H2,2,3,3-四甲基環丙基幾基)氧基-雄],4•二稀傅叛酸 使用如中間物5所述類似之方法,自㈣dUWh-二經基I·甲基-3·氧代·雄^二稀-導竣酸(G. Η. 制顿等人,(1994则化學M(Wnal of —
Chemistry),37,3717-3729)及 2 ) 2 ^ “ ;汉2,2,3,3-四甲基環丙基碳醯氯 製備。LCMS駐留時間3.75分鐘。 中間物18 : 17α-(5-氣-4·甲齑龙· *、 Τ乳基-嘍吩-3-羰基)氧基-6α,9α- 二氣-11/3-經基-16α_甲基·3·氧代·雄·ΐ4二稀得援酸 使用如中間物5所述類似之方法製儀。_駐留時間 3.59分鐘。 中間物19 · 17α-(2,2-二氣·3,3.二甲基環丙基擬基)氧基 二氣-⑽經基七甲基_3_氧代雄Μ二稀得 羧酸 使用如巾間物1所述類似之方法製備。匕⑽^駐留時間 3 · 5 8分鐘。 中間物20 : 17«-(2,2-二氣·3,3_二甲基環丙基羰基)氧基 -6«,9«-二氟-Π&羥基·16α_甲基_3_氧代雄_1>4•二烯_17卜 羥硫代睃 使用如中間物1所述類似之方法製備。LCMS駐留時間 4.10,4.19分鐘。 中間物21 : 17〇Η環己基羰基)氧基_6α,9α_二氟_n心羥基 -16〇^-甲基-3-氧代-雄-1,4_二烯-17心羥硫代酸 使用如中間物1所述類似之方法製備。LCMS駐留時間 94506.doc -42- 4 · 17分鐘。 中間物22 : 6α,9α-二襄_11/3·經基·Ι6α-甲基_nM5甲基磺 醯基·嘧吩-2-羰基)氧基氧代-雄二烯_17心羥硫代睃 使用如中間物i所述類似之方法製備。^默駐留時間 4.1〇分鐘。 中間物23 : 6α,9…二氣·⑽-經基·16〜子基_3氧代·.a 三氟甲基-呋喃-2-羰基)氧基-雄-1,4_二烯_17/3_羥硫代酸 使用如中間物1所述類似之方法製備。LCMSK留時間 4·45分鐘。 中間物24 : 6«,9«-二氟·17„·(3_二氟甲基硫基)节酿基)氧基 11/3-羥基-16α-甲基-3-氧代-雄-1,4-二烯·17卢_羥硫代酸 使用如中間物i所述類似之方法製備。LCMSe留時間 4 · 2 3分鐘。 中間物25.2,3-二甲基-1_((2,2,3,3-四子基環丙基)幾基)_111_ 咪唑-3·鑕氯化物 在34°C及65分鐘内,將草醯氣(36〇毫升,4 1莫耳)添加於 έ 2,2,3,3-四甲基環丙院缓酸(6〇〇克,4.2莫耳)之二氣甲院 (3.6升)攪拌溶液中。再使溶液加熱至回流3〇分鐘,接著冷 部至5 C。將内溫維持在約5°c且於45分鐘内添加含丨,2•二甲 基咪唑(490克,5.1莫耳)之二氣甲烷(丨.2升)溶液。所得懸浮 液在升溫至18t,且將内溫維持在約18t下於45分鐘内添 力丙酮(4.8升),在5 C下搜拌3 0分鐘,接著過瀘以過遽收 集產物,以丙酮··二氣甲烷(3 : 1,3χ12升)洗滌,抽氣脫 水再於25-30°C之真空烘箱尹乾燥〗〇小時,獲得白色固態中 94506.doc -43-
間物 25(890克)。4 NMR: δΗ (CDC13,400MHz) 8.45 (d,J 2.4Hz, 1H), 8.11 (d, J 2.4Hz, 1H), 4.21 (s, 3H), 2.96 (s, 3H), 2.21 (s,1H),1.43 (s,6H),1·33 (s,6H)。 實例 實例 1 : 6α,9α-二氟-11 尽-經基-16α-甲基-3-氧代-ΐ7α-(2,2,3,3-四甲基環丙基羰基)氧基-雄-1,4-二烯·17/?·羥硫代酸s-氰基 甲酯 在氮氣中,將溴乙腈(0.042毫升,0.6毫莫耳)添加於含中 間物1(120毫克’ 0.22毫莫耳)及碳酸氫鈉(21毫克,0 245毫 莫耳)之DMF(3毫升)搜拌及冷卻(冰)溶液中,且使混合物在 室溫下攪拌18小時。添加二乙胺(〇.03毫升,〇 29毫莫耳), 且於添加2M HC1 (4毫升)接著添加水(5毫升)及二氣甲炫(5 毫升)後使混合物攪拌15分鐘。分離有機相,依序以碳酸氫 鈉水溶液(5毫升)及食鹽水(5毫升)洗滌,且經親水性玻璃質 脫水且蒸發至乾。在Bon Elut盒上先使用環己烷最後使用環 己烷:乙酸乙酯3 : 1純化,獲得標題化合物(86毫克):lCms 駐留時間3.82分鐘,〇1/2 576 1\411+。 實例2 : 丨(二乙基胺基)磺醯基】苄醯基)氧基·6α9α_ 一氣-11/S-經基-16α-甲基_3_氧代ϋ4_二稀_17尽·經硫代 酸S-氰基甲酯 實例2係使用如實例w述類似之方法,自中間物2製備。 LCMS駐留時間3 62分鐘,m/z 691 ΜΗ+。 實例3 : 氣-4-甲氧基·,塞吩·域基)氧基_6—二氣 卩羥基16α-甲基-3-氧代-雄·L4-二烯_17jS•羥硫代酸s_ 94506.doc -44- 1338694 氦基甲酯 實例3係使用如實例!所述類似之方法,自中間物3製備。 LCMS駐留時間 3.58分鐘,m/z 626/628 MH+。 實例 4 : 6α,9α-二氟-11 心羥基_i6〇r-f 基-3·氧代_ΐ7α-(2,2,3,3-
四甲基環丙基羰基)氧基-雄-1,4-二烯-17/3-破酸氱基甲酯 方法A 在氮氣中’將溴乙腈(0.229毫升,3.29毫莫耳)添加於含 中間物4(634毫克,1.22毫莫耳)及碳酸鈉(1.29克,12 2毫莫 耳)之DMF(15毫升)攪拌且冷卻(冰)溶液中,且使混合物在 室溫下攪拌2小時。添加更多碳酸鈉(258毫克),且使混合物 再攪拌18小時。滴加2M HC1(20毫升),接著加水(25毫升), 且以乙酸乙酯(2x25毫升)萃取混合物。合併之有機萃取液依 序以碳酸氫鈉水溶液(50毫升)及食鹽水(5〇毫升)洗滌,且經 親水性玻璃質脫水且蒸發至乾。在5〇11幻111盒上先使用環己 烷最後使用環己烷··乙酸乙酯3 : 1純化,獲得白色固態標 題化合物(485毫克):1^]^駐留時間3.79分鐘,111/2560 MH、
方法B 將 6α,9ο:-二氟-11/3,17α _二羥基·ι6α_ 甲基 _3_氧代 m4_ 二烯-l%-羧酸(490克,1.2莫耳)及中間物25(79〇克,3丨莫 耳)懸浮於3-戊酮(7.3升)中。在10分鐘内且内溫維持在19<t 下,於稅拌之懸浮液中添加含1,2_二甲基σ米唾(12〇克,I〗 莫耳)之水(730毫升)溶液。35分鐘後,使内溫維持在約19 C且於10分鐘添加1 -甲基哌畊(23〇毫升,2.丨莫耳)。使混合 94506.doc •45· 1338694 物攪拌30分鐘’接著依序以2M HC1(290毫升)及水(290毫升), 洗滌。將二異丙基乙胺(430毫升,2.5莫耳)及溴乙腈(120毫 升,1.7莫耳)依序添加於溶液中,且使混合物加熱至53! 3 小時。溶液冷卻至34°C,且添加1-曱基哌畊(105毫升)。混 合物在約34°C下在攪拌一小時,冷卻至25°c,且依序以2m HC1(290毫升)、水(290毫升)、2%碳酸鉀溶液(290毫升)及水 (290毫升)洗滌。有機溶液藉由大氣壓蒸餾濃縮至3 9升,冷 卻至75°C,且以實例4之結晶播晶。在75t:下於3小時内添 加二曱基戊烧(6.83升),再使漿料於2小時内冷卻至1 〇。〇, 再攪拌30分鐘接著過濾。產物以3_戊酮:2,2,4-三甲基戊烷 (1 : 3,3x1升)洗滌,抽氣乾燥,最後在5(rc之真空烘箱中 乾燥12小時,獲得與使用方法A所得物質相同之白色固態 (640克)實例4。 實例5 . 17α-(環己基羰基)氧基·6α,9α_二氟_u卢羥基·ΐ6α_ 甲基-3-氧代-雄·ι,4-二烯-17/3-羧酸氰基甲酯 實例S係使用與實例4所述類似之方法,自中間物s製備。 LCMS駐留時間3 65分鐘,m/z 546 MH+。 實例6 : 6«,9«-二氟-17α_(2,6_二氟芊醯基)氧基·u心羥基 -16α-甲基-3_氧代-雄_14·二烯·17/?羧酸氪基甲酯 實例6係使用與實例4所述類似之方法,自中間物6製備。 LCMS駐留時間3 48分鐘,m/z 576 ΜΗ+。 實例7 : 6α,9α_二氟-11/3_羥基-17α·(4_甲氧基苄醯基)氧基 _16〜甲基_3-氧代-雄-1,4-二烯-17/3-羧酸氰基f酯 實例7係使用與實例4所述類似之方法,自中間物7製備。 94506.doc -46· LCM^£ 留時間 3.53分鐘,m/z 570 MH+。 實例8 17〇;-(4·氰基芊醯基)氧基_6α 9α二氟羥基_16α_ 甲基_3_氧代-雄-1,4-二烯-17心羧酸氰基甲酯 實例8係使用與實例4所述類似之方法,自中間物8製備。 LCMS駐留 β寺間 3 44分鐘,m/z 565 ΜΗ+。 實例9 : 17α_(環戊基甲基羰基)氧基-6α,9α-二氟-11〆經基 _16〇ί•甲基_3-氧代·雄-1,4-二烯-17/3-羧酸氰基甲酯 實例9係使用與實例4所述類似之方法’自中間物9製備。 LCMS駐留時間3 69分鐘,m/z 546 μη+。 實例10: 6α,9α-二氟-17α·(3,3_二甲基丁醢基)氧基u尽羥基 -16α-甲基-3-氧代-雄^,^二烯_17心羧酸氰基甲酯 實例10係使用與實例4所述類似之方法,自中間物1〇製 備。LCMS駐留時間3 6〇分鐘,m/z 534 ΜΗ+。 實例11 : 6〇f,9os二氟_n心羥基_17α_(2_異丙基_13嘧唑_4_ 羰基)氧基-16心曱基-3-氧代-雄-1,4_二烯-17心羧睃氰基甲 酯 實例11係使用與實例4所述類似之方法,自中間物U製 備。1^〇\48駐留時間3.50分鐘,111/2 589 1^11+» 實例12 : 6〇f,9〇f-二氟心經基·16α_甲基_3_氧代_17卜(啥淋 •2-幾基)氧基-雄_1,4_二烯-17/3_羧酸氰基甲酯 實例12係使用與實例4所述類似之方法’自中間物12製 備。LCMS駐留時間3.61分鐘,m/z 591 ΜΗ+。 實例13 : 6α,9α-二氟_u心羥基_16α_甲基_3_氧代17α·(5三 敗甲基-吹喊-幾基)氧基-雄-1,4 -二稀-17j3-幾酸氣基甲酿 94506.doc • 47· 1338694 實例13係使用與實例4所述類似之方法,自中間物工3製. 備。1^:\18駐留時間3.72分鐘,111/2 5 98;\111+。 . 實例I4 : 6α,9α-二氟心羥基_16Qf_甲基_ηα_(5甲基磺醯 基塞吩-2-羰基)-3-氧代-雄_Μ_二烯_17卜羧酸氰基甲酯 實例14係使用與實例4所述類似之方法,自中間物14製 備° LCMS駐留時間3,29分鐘,m/z 624 ΜΗ+。 實例15 : 6α,9α-二氟-11爲·羥基-16α-甲基-17α-(5-甲基硫基_ 嶁吩-2-羰基)氧基氧代―雄“,‘二烯_17心羧酸氰基甲酯 實例15係使用與實例4所述類似之方法,自中間物15製 參 備°1^1^8駐留時間3.64分鐘,111/^ 5 92 ^^+。 實例16 . 6α,9α-二氟·17α-(5-乙基-異噚唑-3-羰基)氧基-llj8_ 羥基-16α_甲基·3-氧代-雄·1,4_二烯-17沒-羧酸氰基甲酯 實例16係使用與實例4所述類似之方法,自中間物16製 · 備》LCMS駐留時間3 44分鐘,m/z 559順+。 實例17 : 9α-氟·ΐι心羥基_16卜甲基_3_氧代-17〜(2,2,3,3_四 甲基環丙基羰基)氧基_雄_14_二烯_17j3_羧酸氰基甲酯 實例17係使用與實例4所述類似之方法,自中間物17製 備。LCMS駐留時間3 77分鐘,m/z 542 mh+。 實例 18 6α,9α 一氟-11/3-經基-16ο:-甲基-3-氧代-17α-(2,2,3,3_ 四甲基環丙基幾基)氧基-雄-4-稀-17/3-叛酸氰基甲酯 使含實例4(1.8克,3.2毫莫耳)及Wilkinson's觸媒(〇·5克, * 0.54毫莫耳)之甲笨與乙酸乙酯2 :丨混合物(13〇毫升)溶液氫 化5天。1天後添加另一批觸媒(〇 5克)。蒸發溶液且使殘留 物在100克矽膠盒上,15分鐘内先使用環己烷:乙酸乙酯 94506.doc -48- 1338694 0-30¼梯度’接著使用環己烷:乙酸乙酯3〇% 1〇分鐘層析。 合併適當之鶴份且蒸發,獲得白色固態標題化合物(400毫 克):LCMS駐留時間 3 73分鐘,m/z 579 MNH4+。 實例19: 17α-(5-氣_4-甲氧基-嘧吩_3_羰基)氧基_6α,9α_二氟 羥基-16α-甲基_3•氧代_雄_14_二烯_17卢羧酸氰基甲 酯 實例19係使用與實例4所述類似之方法,自中間物18製 備。LCMS駐留時間 3.57分鐘,m/z 61〇, 612 ΜΗ+。 實例20 · 17α-(2,2·二氣·3,3·二甲基環丙基羰基)氧基·6α 9α_ 二氟-11卜羥基-16α_甲基-3-氧代-雄-1,4-二烯-17心羧酸氰 基甲酯 實例20係使用與實例4所述類似之方法自中間物u製 備。LCMS駐留時間 3 62分鐘,m/z 6〇〇, 6〇2, 6〇4 μη+。 實例21: 17〇K2,2-U,3_二甲基環丙基幾基)氧基_6α9α_ 一氟-11卢-羥基_16以·甲基_3_氧代_雄_1,4-二烯_17沒-羥硫代 酸s-氛基甲酯 實例21係使用與實例1所述類似之方法,自中間物20製 備 LCMS駐留時間 3.58分鐘,m/z 616, 618, 620 ΜΗ+。 實例22 · 17α·(環己基羰基)氧基-6α,9α-二氟-ii/s-羥基_16α_ 甲基-3-氧代··雄-:^心二烯_17心羥硫代酸s_氰基甲酯 實例22係使用與實例1所述類似之方法,自中間物21製 備。LCMS駐留時間3_6〇分鐘,m/z 562顧+。 實例23 · 6α,9α-二氟·ιι尽·羥基_16〇f_甲基17α_(5甲基續醢 基-嘍吩-2-羰基)氧基_3_氧代-雄“,^二烯_17心羥硫代酸& 94506.doc -49- 1338694 氰基甲酯 實例23係使用與實例1所述類似之方法,自中間物22製 備LCMS駐留時間3 3〇分鐘,—㈣廳+。 實例24 ^’9«-二氟]1/?·經基_ϊ6α甲基_3氧代杨(&三 氣甲基·咬H幾基)氧基-雄-Μ-二稀-導經硫代酸s_氣 基甲酯 實例24係使用與實例1所述類似之方法,自_間物23製 備。LCMS駐留時間3.6〇分鐘,_614圓+。 實例2S : 6α,9α_二氟·17M3_(二氟甲基硫基)苄醯基)氧基 /3經基16α·甲基_3_氧代·雄_ι,4_二婦_17/3_經硫代酸s_ 氰基甲酯 實例25係使用與實例述類似之方法,自中間物“製 備。LCMS駐留時間3.65分鐘,m/z㈣MH+。 醫藥活性 醫藥活性可依類糖皮質素促效活性之功能性活體分析分 析。 以 Κ·Ρ‘Ray等人,生化期刊(Biochem J). (1997),328, 707-715所述為準之功能性分析提供類糖皮質素促效劑反 壓抑活性之測量》以含有來自與sPAp(分泌之鹼性磷酸酶) 偶合之ELAM基因促進劑之NF-kB反應元素之受體基因安 定感染之A549細胞在37°C下以適當劑量之試驗化合物治療 1小時。該等細胞再以腫瘤壞死因子(TNF,丨〇叩/毫升)刺激 16小時’此時產生之鹼性磷酸酶量以標準比色分析測量。 建構劑量反應曲線,且由該曲線可估算Ec5()值。 94506.doc •50- 1338694 實例1至25化合物之EC5G值<10 nM。 實例1至11,14至22及25發現之EC5G值<1 nM,且實例4、 8、15及20發現之EC5〇值為S0.1 nM。 以 R.J.H. Austin等人,Eur Resp J· (2002),20,1386-1392 所述為準之功能性分析測量化合物直接反活化基因表現之 能力。以含有與renilla蟲螢光素酶偶合之老鼠乳房腫瘤病毒 長封端重複(MMTV-LTR)之類糖皮質素之受體基因安定感 染之A549細胞在37。〇:下以適當劑量之試驗化合物治療6小 時。再藉由測量發出之光,接著以適當之基材培養測定細 胞中存在之蟲螢光素酶活性量。建構劑量反應曲線,由該 曲線可估算EC”值,且由該曲線可計算相對於地美色松 (Dexamethasone)(100%)之最大反應。 實例1至25之化合物在該分析中顯示之最大反應<35〇/〇。 實例1、2、4、5、6、9至11、13及15至25之化合物在該 分析中顯示之最大反應<20%。 實例2及4之化合物在該分析中顯示之最大反應<5〇/〇。 proqesterone受體活性之分析 人類乳房癌細胞株T47D已經被提出向上調節反應黃體 激素之内升鹼性磷酸酶((Di L〇renzo等人,癌症研究(Cancer
Research) (1991) 51,4470-4475)。T47D細胞係以每洞之密
度為1X105細胞播晶於96洞版中,且在37。(:下生長隔夜。將 類固醇溶於DMSO中,添加於細胞中(最終之DMS〇濃度為 0·7 /〇) ’且在37 C下培養24小時。細胞再以PBS洗蘇,且以 RIPA緩衝液(含 1% IGEPAL,0.5% Na去氧膽酸鹽,〇,1% SDS 94506.doc 51 1338694 磷酸鹽緩衝之食鹽水)使細胞溶解。鹼性磷酸酶活性係使用 溶於1 Μ二乙醇胺、〇_28 M NaCl、0.5 mM MgCl2之對_硝美 苯基磷酸鹽(1.5毫克/毫升)作為基材測量。建構劑量反應曲 線’且由該曲線估算EC5〇值。 實例4、5、8、II、18、20、23、24及25化合物在該分析 中之 EC50值 >1〇〇 nM。 說明書及隨後之申請專利範圍全文中,除非另有說明, 否則”包括”及其變體將了解係指所列之整體或步驟,或整
體之群組,但並不排除其他整體或步驟或整體或步驟 組。 形成敘述或申請專利範圍部分之申請案可用作任一後續 =相關之前案之基礎。該後續申請案之申請專利範圍 八物、本文所述任何特點或特點之結合。其可為產物、組 ㈣用^法或主張之用途之形式,且可包含(僅為列舉且非 艮制用)以下申請專利範圍。 本申請案中所述之專利及專
考。 寸〜τ °月茱均併入本文中供參 94S06.doc -52-
Claims (1)
1338694 h:,]?日修(更)正本I Iav %彳2〇7〇7號專利申請案 Ρ專利範圍替換本(99年4月) 十、申請專利範圍 1. -種下式⑴之化合物’或其生理上可接受性鹽:
其中 X代表0或S ; Ri代表Cw烷基、CM環烷基、c3 8環烷基甲基或C3 8環烯 基’、任4固均可視情況以一或多個甲基或鹵素原子取 代,或 Ri代表芳基、經取代之芳基、雜芳基或經取代之雜芳基; R2代表氣、甲基,其可爲《或β結構,或爲亞甲基; R3及爲相同或不同,且各獨立代表氫、鹵素或甲基; 且代表單鍵或雙鍵。 2·如請求項丨之化合物’其中χ代表〇。 3‘如°月求項1或2項之化合物,其中Ri代表視情況以一或多 個曱基或氣基取代之(:3_6環烷基。 4.如°月求項1或2之化合物,其中R!代表2,2,3,3-四甲基環丙 94506-990409.doc 1338694 5·如請求項1或2之化合物,其中R2代表α-結構之曱基。 6·如請求項1或2之化合物,其中及R4均為氟。 7·如請求項1或2之化合物,其中一代表雙鍵。 8.如請求項1或2之化合物,其為 6α,9α-二氣-11β-羥基-16α-曱基-3-氧代-17〇1-(2,2,3,3-四甲 基環丙基羰基)氧基-雄-1,4-二烯-17β-羥硫代酸s-氱基甲 酯; 17α-(4-[(二乙基胺基)磺醯基]芊醯基)氧基_6α,9α-二氟 -1 1β-經基_1 6α-曱基-3 -氧代-雄-1,4-二稀-1 7β-經硫代酸S- 氰基曱酯; 17α-(5 -氯-4-曱氧基-57基吩-3-羧基)氧基- 6α,9α-二氣-ΐΐβ-羥基-1 6α-甲基-3 -氧代·雄-1,4-二烯-1 7β-羥硫代酸S-氰基 曱酯; 17α-(環己基羰基)氧基-6α,9α-二氟-ΐΐβ-羥基-16α-甲基-3-氧代-雄-1,4-二烯-17β-羧酸氰基曱酯; 6〇1,9〇1-二氣_17〇'-(2,6-· — 氟》卞酿基)氧基-11β -經基-16α-甲 基-3-氧代-雄-Μ-二烯-17β-羧酸氱基曱酯; 6〇1,9〇1-二氟-110-羥基-17〇1-(4-曱氧基芊醯基)氧基-16〇1-甲 基-3-氧代-雄-Μ-二烯-17β-羧酸氰基曱酯; 17α-(4-氰基芊醯基)氧基-6α,9α-二氟-ΐΐβ-羥基-16α-甲基 -3-氧代-雄-1,4-二烯-17β-羧酸氰基曱酯; 17α-(環戊基曱基羰基)氧基-6α,9α-二氟-11β-羥基-16α-曱 基-3-氧代-雄-I,4·二烯·17β·羧酸氰基曱酯; 6〇1,9〇1-二氟_17〇1_(3,3-—曱基丁酿基)氧基-110-經基-16〇1- 94506-990409.doc -2- 1338694 曱基-3-氧代-雄-1,4-一烯-17β-敌酸氱基曱酷; 6L二氟-11P-經基-17α·(2_異丙基_!,3♦坐冰幾基)氧 基物-甲基I氧代冬Μ•二稀_17_酸氰基甲酿; 6α,9α-二氟-11β_羥基-16α-曱基·3_氧代_ηα (峻啉_2羰 基)乳基-雄-1,4 -二細·17β -緩酸氰基曱醋· 6α,9α-二氟-Ηβ-羥基_16α_甲基_3_氧代_17α (5三氟甲基_ 呋喃-2-羰基)氧基·雄-丨,4_二烯_丨邛_羧酸氰基曱酯; 6α,9α-二氟-11β-羥基-16α•甲基]7α_(5•甲基磺醯基嶁吩 -2-羰基)-3-氧代-雄-1,4-二烯-ΐ7β_羧酸氰基曱酯; 鲁 6α,9α-二氟-11β-羥基-16α-甲基·17〇1_(5_甲基硫基—塞吩_2-羰基)氧基-3-氧代-雄-1,4-二稀-1 7β-叛酸氰基曱酯; 一 6α,9α-二氟-17α-(5-乙基-異呤唑-3-羰基)氧基_丨〗β_羥基 “ -16α-曱基-3-氧代-雄-1,4·二烯-17β-羧酸氱基曱醋; 9(1-氟-110-羥基-160-甲基-3-氧代-17〇1-(2,2,3,3-四甲基環 丙基羰基)氧基-雄-1,4-二烯-17β-羧酸氰基甲酯; 6α,9α-二氟-11β-羥基-16α-甲基-3-氧代-17α-(2,2,3,3-四甲 _ 基環丙基羰基)氧基-雄-1,4-二烯-Ι7β-羧酸氰基曱酯; 17〇1-(5-氣-4-曱氧基-0塞吩-3-幾基)氧基-6〇1,9〇1-二氟-110-羥基-16α-曱基-3-氧代-雄-4-烯·17β-羧酸氰基曱酯; 17α-(2,2-二氣-3,3-二甲基環丙基羰基)氧基-6α,9α-二氟 -11β-羥基-16α-曱基-3-氧代-雄-1,4-二烯-17β-羧酸氰基甲 酯; 17〇1-(2,2-二氣-3,3-二甲基環丙基羰基)氧基-6〇1,9(1-二氟 -1 1 β-經基-1 6α-曱基-3-氧代-雄-1,4-二烯-1 7β-經硫代酸S- 94506-990409.doc 1338694 氰基甲酯; l7〇t-(環己基幾基)氧基‘6α,9α_二氣 氧代-雄_ 1,4-二烯-1 7β-羥硫代醆s_ 基-3- 6α,9α-二氟-11β-經基 _i6ct-甲 -2-羰基)氧基-3-氧代_雄-丨,4_ δ旨; • 11 β-經基-1 6α-甲 氰基甲酯; &·17α-(5-曱基磺醯基-嘧吩 二烯-Ι7β·羥硫代酸S—氱基甲
呋喃-2-羰 酉旨;或 基)氧基-雄-1,4 -二烯_ i 7卜經硫代酸s _氛基甲 ,a 一氟i7a-(3-(一氟曱基硫基)节醯基)氧基·^ ^卜經 土 16a-甲基-3-氧代-雄_ι,4-二烯_ΐ7β_經硫代酸s·氣基甲 酯。 9.如請求項8之化合物,該化合物為 6a,9a-二氟 _11β·經基 _16a_ 甲基 _3•氧代 _17〇^2,2,3 3_四甲 基%丙基羰基)氧基-雄-1,4-二烯_ι7β_羥硫代酸8_氰基甲 酯; 9α·氟-ΐΐβ·羥基_16β_甲基_3_氧代_17α_(2,2,33四甲基環 丙基#厌基)氧基-雄_ 1,4-二稀_ 1 7β-缓酸氰基甲醋; l7cK環己基羰基)氧基-6α,9α-二氟-11β-羥基·16α_甲基_3· 氧代-雄-1,4-二烯-Ι7β-羧酸氰基甲酯; 17α-(環戊基曱基羰基)氧基_6α,9α•二氟_up羥基甲 基-3-氧代-雄-1,4-二烯-17β-羧酸氰基甲酯; 6α,9α-二氟-17α-(3,3-二甲基丁醯基)氧基-1ΐβ_羥基·16心 甲基-3-氧代-雄-〗,4-二烯_ΐ7β-羧酸氰基甲酯; 94506-990409.doc 6α’9α-二氟-17α-(3-(二氟曱基硫基)芊醯基)氧基-ΐΐβ-羥 基-16(χ-曱基-3-氧代-雄-1,4-二烯-17β-羥硫代酸S-氰基甲 酯; 17cK環己基羰基)氧基-6α,9α-二氟-11β-羥基-16α-甲基-3-氧代-雄-1,4-二烯-17β-羥硫代酸S-氰基曱酯; 6α’9α'二氟-17α-(5-乙基-異噚唑-3-羰基)氡基·ηβ·羥基 •Ι6α~甲基-3-氧代-雄-1,4-二烯-17β-羧酸氰基曱酯; 6α’9〇ι-二氟-11β_羥基-16α-甲基-17α-(5-甲基硫基-ο塞吩-2-&基)氧基-3-氧代-雄-1,4-二烯-17β-羧酸氰基甲酯; 6α,9α'二氟_11β-羥基-17α-(2-異丙基_ι,3_Ρ塞唑_4_獄基)氧 基16α-甲基_3_氧代-雄-1,4-二烯叛酸氰基甲酯; 17cK2,2-二氣-3,3-二甲基環丙基羰基)氧基·6α,9α_二氟 UP-麵基-16α-甲基-3-氧代-雄-l,4_二烯·170_羥硫代酸s-氰基甲酯;或 17〇1-(2,2-二氣-3,3-二甲基壞内基羰基)氧基_6〇1,9〇1_二氟 UP-麵基-16α-甲基-3-氧代-雄-ΐ,4_二烯_17β_羧酸氰基曱 S旨。 10. 如請求項9之化合物,該化合物為 H(2,2-二氣-3,3-二甲基%内基羰基)氧基_6α,9(χ_二氟 -ιΐβ-經基物-甲基-3-氧代-雄],4、二稀叩繞酸氣基甲 酿;或 6α,9α-二敦_lip_經基物_甲基、3_氣代Km;-四甲 基環丙基羯基)氧基-雄-1,4-二场,_經硫代酸氣基甲 酯。 94506-990409.doc 1338694 11. 如請求項1或2之式(1)化合物或其生理上可接受性鹽化合 物’其係用作獸醫或人類用醫藥。 12. 一種如請求項!或2之式⑴化合物或其生理上可接受性鹽 化合物用於製造治療發炎及/或過敏性症狀之藥劑之用 途0 13. 一種醫藥組合物,其包括如請求項第1或2項之式⑴化合 物或其生理上可接受性鹽化合物,且若需要可與一或多 種生理上可接受之稀釋劑或載劑混合。
14‘一種醫藥氣溶膠調配物,其包括如請求項第丨或2項之式 ⑴化合物或其生理上可接受性鹽化合物,及氟碳化合物 或含氫之氣氟碳作為推進劑,且可視情況與界面活性劑 及/或共溶劑倂用。 15·如請求項第U項之醫藥組合物’尚包括另一種治療活性 刈,其選自消炎劑、反副交感神經作用劑,…腎上腺素 受體促效劑、抗感染劑或抗組織胺。 16. 如請求項第15項之醫藥組合物,其中該另—種醫藥活性 劑為βρ腎上腺素受體促效劑。 17. -種如請求項之式⑴化合物或其生理上可接受性雖 化合物在製造供治療具有消炎及/或過敏症狀之人類或: 物標的之藥劑之用途。 18. —種化合物,該化合物為 1 7α·(4-[(二乙基胺基)磺醯基]苄醯基)氧基_6α,9α_二氣 β L基-16α·曱基-3-氧代-雄-μ-二烤·17卜經硫代醆 94506-990409.doc 基-3-氧代-雄-1,4-二烯-17β-羧酸 6〇1,9(1-二氟-110-羥基-17〇1-(4-曱氧基芊醯基)氧基-16〇1-曱 基-3-氧代-雄-1,4-二烯-17β-羧酸 17〇1-(4-氰基爷酸基)氧基-6〇1,9〇1-二|^-110-經基-16(1-曱基 -3-氧代-雄-1,4-二烯-17β-羧酸 6α,9α-二氟-17α-(3,3-二甲基 丁醯基)氧基-11β-羥基-16α-甲基-3-氧代-雄-1,4-二烯-17β-羧酸 6α,9α-二氟-11β-羥基-17α-(2-異丙基-1,3-噻唑-4-羰基)氧 基-16α-曱基-3-氧代-雄-1,4-二烯-17β-羧酸 6ct,9ct -二氣- ΙΙβ-經基-16α-曱基-3 -氧代-17α-(口奎 17林-2-幾 基)氧基-雄-1,4 -二細-17β -缓酸 6α,9α-二氟-11β-羥基-16α-甲基-3-氧代-17α-(5-三氟甲基- 呋喃-2-羰基)氧基-雄-1,4-二烯-17β-羧酸 6〇1,9(1-二氣-110-經基-16〇1-甲基-17〇1-(5-甲基石黃酿基-17塞吩 -2-羰基)-3-氧代-雄-1,4-二烯-17β-羧酸 6α,9α-二氟-11β-羥基-16α-曱基-17α-(5-曱基硫基-嘧吩-2- 羰基)氧基-3-氧代-雄-1,4-二烯-17β-羧酸 6α,9α-二氟-17α-(5-乙基-異哼唑-3-羰基)氧基-11 β-羥基 -1 6α-甲基-3-氧代-雄-1,4-二烯-17β-羧酸 17ct-(5 -氣-4 -曱乳基-ρ塞吩-3-罗炭基)乳基- 6α,9α-二敦-ΙΙβ- 羥基-1 6α-曱基-3-氧代-雄-1,4-二烯-1 7β-羧酸 17ct-(2,2-二氣-3,3-二曱基環丙基羰基)氧基-6α,9α-二氟 -11 β -經基-1 6 α -甲基-3 -氧代-雄-1,4 -二稀-1 7 β -竣酸 17α-(2,2-二氣-3,3-二甲基環丙基羰基)氧基-6α,9α-二氟 94506-990409.doc -ιΐβ-經基-16α-甲基_3-氧代_H,4_二稀谱經瑞代酸 6«,9〇1-二氟_1小經基_16心甲基_1^(5_甲基續醯基_4吩 -2-幾基)氧基_3_氣代_雄],4_二稀-導經硫代酸 Μ'二氟七卜羥基_16α_甲基-3-氧代·17α_(5_三氟甲基· m難)氧基养m17(3m㈣,或 ’ 氟17α-(3-(二氟甲基硫基)苄醯基)氧基-11β-羥 19 基_16α_甲基~3·氧代雄-1,4-二稀-17β-經硫代酸。 —種下式(IV)之化合物: 0
(IV) 該化合物為之义二甲基+旧’^^四甲基環丙基)· 基]-1Η-咪唑_3·鑌氣化物。 0_ —種製備下式(Π)化合物之方法, 94506-990409.doc
、中R丨代表2,2,3,3-四曱基環丙基,且r2、r3、R4、X及 均如請求項1至7中任一項之定義,該方法包括使2,23,3_ 四甲基環丙烷羧酸(IV)之ι,2-二曱基_1H_咪唑酯: 1338694 〇
與下式(III)之相對應17α-羥基衍生物反應
21·如請求項20之方法,其中之X代表0。 94506-990409.doc
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0316290.6A GB0316290D0 (en) | 2003-07-11 | 2003-07-11 | Novel compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200524954A TW200524954A (en) | 2005-08-01 |
TWI338694B true TWI338694B (en) | 2011-03-11 |
Family
ID=27742019
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093120698A TWI367888B (en) | 2003-07-11 | 2004-07-09 | 6α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-(2,2,3,3-tetramethylcyclopropylcarbonyl)oxy-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester, composition comprising the same, and use thereof |
TW093120707A TWI338694B (en) | 2003-07-11 | 2004-07-09 | Novel compounds |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093120698A TWI367888B (en) | 2003-07-11 | 2004-07-09 | 6α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-(2,2,3,3-tetramethylcyclopropylcarbonyl)oxy-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester, composition comprising the same, and use thereof |
Country Status (31)
Country | Link |
---|---|
US (6) | US7291609B2 (zh) |
EP (3) | EP1644397B1 (zh) |
JP (3) | JP4709752B2 (zh) |
KR (2) | KR101029207B1 (zh) |
CN (3) | CN1845933B (zh) |
AR (2) | AR045900A1 (zh) |
AT (1) | ATE467638T1 (zh) |
AU (2) | AU2004255855B2 (zh) |
BR (2) | BRPI0412526A (zh) |
CA (2) | CA2531905C (zh) |
CY (2) | CY1110149T1 (zh) |
DE (1) | DE602004027137D1 (zh) |
DK (2) | DK1644397T3 (zh) |
ES (3) | ES2433665T3 (zh) |
GB (1) | GB0316290D0 (zh) |
HK (2) | HK1089186A1 (zh) |
HR (2) | HRP20100359T1 (zh) |
IL (3) | IL172777A (zh) |
IS (3) | IS2909B (zh) |
MA (2) | MA27899A1 (zh) |
MX (2) | MXPA06000443A (zh) |
MY (2) | MY137944A (zh) |
NO (2) | NO333263B1 (zh) |
NZ (2) | NZ544577A (zh) |
PL (2) | PL1644397T3 (zh) |
PT (2) | PT1644397E (zh) |
RU (3) | RU2359973C2 (zh) |
SI (2) | SI1644398T1 (zh) |
TW (2) | TWI367888B (zh) |
WO (2) | WO2005005452A1 (zh) |
ZA (2) | ZA200600226B (zh) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0125259D0 (en) * | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
GB0316290D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
DE102004025966A1 (de) * | 2004-05-21 | 2005-12-15 | Schering Ag | Estradiol-Prodrugs |
DE102004025985A1 (de) * | 2004-05-21 | 2005-12-15 | Schering Ag | Estriol- und Estetrol-Prodrugs |
US20090124588A1 (en) * | 2005-01-10 | 2009-05-14 | Glaxo Group Limited | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions |
ATE517908T1 (de) * | 2005-01-10 | 2011-08-15 | Glaxo Group Ltd | Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände |
EP1879620A2 (en) * | 2005-03-30 | 2008-01-23 | Schering Corporation | Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist |
EP1921919B1 (en) | 2005-07-14 | 2012-04-04 | Lithera, Inc. | Sustained release enhanced lipolytic formulation for regional adipose tissue treatment |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
ES2388351T3 (es) | 2006-04-20 | 2012-10-11 | Glaxo Group Limited | Compuestos novedosos |
GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
WO2008048770A1 (en) * | 2006-10-17 | 2008-04-24 | Lipothera, Inc. | Methods, compositions, and formulations for the treatment of thyroid eye disease |
AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
MX2010012814A (es) | 2008-05-23 | 2010-12-20 | Amira Pharmaceuticals Inc | Inhibidor de proteina activadora de 5-lipoxigenasa. |
US8163743B2 (en) | 2008-06-05 | 2012-04-24 | GlaxoGroupLimited | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases |
WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
US20100160351A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
JP5656880B2 (ja) | 2009-03-09 | 2015-01-21 | グラクソ グループ リミテッドGlaxo Group Limited | Pi3キナーゼの阻害剤としての4−オキサジアゾール−2−イル−インダゾール |
JP2012520257A (ja) | 2009-03-10 | 2012-09-06 | グラクソ グループ リミテッド | Ikk2阻害剤としてのインドール誘導体 |
EP2408769A1 (en) | 2009-03-17 | 2012-01-25 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
EP2408915A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010107952A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
BRPI1009271A8 (pt) | 2009-03-19 | 2016-02-10 | Merck Sharp & Dohme | Molécula de ácido nucleico interferente curto de filamento duplo, composição farmacêutica, e, método para tratar um indivíduo humano que sofre de uma condição que é mediada pela ação, ou pela perda de ação, de bach1 |
EP2408458A1 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
JP2012521762A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた神経成長因子β鎖(NGFβ)遺伝子発現のRNA干渉媒介性阻害 |
WO2010111471A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
JP2012521764A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた胸腺間質性リンパ球新生因子(TSLP)遺伝子発現のRNA干渉媒介性阻害 |
WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
AU2010229847A1 (en) | 2009-03-27 | 2011-10-13 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of the intercellular adhesion molecule 1 (ICAM-1)gene expression using short interfering nucleic acid (siNA) |
US8399436B2 (en) | 2009-04-24 | 2013-03-19 | Glaxo Group Limited | N-pyrazolyl carboxamides as CRAC channel inhibitors |
EP2421834A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
LT2899191T (lt) | 2009-04-30 | 2017-10-25 | Glaxo Group Limited | Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai |
US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
KR20120018813A (ko) | 2009-05-29 | 2012-03-05 | 화이자 리미티드 | 글루코코티코이드 수용체 작용제 |
WO2011032175A1 (en) | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
JP2013512878A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | 新規化合物 |
US20120238571A1 (en) | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Indazole derivatives as pi 3-kinase |
GB2477030A (en) * | 2010-01-15 | 2011-07-20 | Lithera Inc | Lyophilised forms of fluticasone, salmeterol and combinations thereof |
WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
US9326987B2 (en) | 2010-09-08 | 2016-05-03 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
WO2012032067A1 (en) | 2010-09-08 | 2012-03-15 | Glaxo Group Limited | Polymorphs and salts of n- [5- [4- (5- { [(2r,6s) -2, 6 - dimethyl - 4 -morpholinyl] methyl} - 1, 3 - oxazol - 2 - yl) - 1h- inda zol-6-yl] -2- (methyloxy) - 3 - pyridinyl] methanesulfonamide |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
EP2630127A1 (en) | 2010-10-21 | 2013-08-28 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
JP5795643B2 (ja) | 2010-10-21 | 2015-10-14 | グラクソ グループ リミテッドGlaxo Group Limited | アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物 |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
CN105832681A (zh) | 2010-11-24 | 2016-08-10 | 纽赛蒂克斯公司 | 选择性、亲脂性及长效型β激动剂单一治疗调配物和用于肥胖及外形凸起的美容治疗的方法 |
US9102671B2 (en) | 2011-02-25 | 2015-08-11 | Novartis Ag | Compounds and compositions as TRK inhibitors |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
US20140005188A1 (en) | 2011-03-11 | 2014-01-02 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
WO2014198909A1 (en) | 2013-06-14 | 2014-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Rac1 inhibitors for inducing bronchodilation |
KR20160062178A (ko) | 2013-10-17 | 2016-06-01 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 호흡기 질병의 치료를 위한 pi3k 억제제 |
JP2016537327A (ja) | 2013-10-17 | 2016-12-01 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 呼吸器疾患の治療のためのpi3k阻害剤 |
JP2017515840A (ja) | 2014-05-12 | 2017-06-15 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | 感染症を治療するためのダニリキシンを含む医薬組成物 |
GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
US20190161480A1 (en) | 2016-08-08 | 2019-05-30 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
US11759472B2 (en) | 2017-11-21 | 2023-09-19 | Cs Pharmaceuticals Limited | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
BR112020008046A2 (pt) * | 2017-11-21 | 2020-10-27 | Axerovision, Inc. | composições e métodos de uso para tratamento de inflamação anormal em glândulas secretoras perioculares ou na superfície ocular |
JP2023519585A (ja) | 2020-03-26 | 2023-05-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | ウイルス感染を予防または治療するカテプシン阻害剤 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3943124A (en) * | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
GB1384372A (en) * | 1971-01-20 | 1975-02-19 | Glaxo Lab Ltd | Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids |
US3686978A (en) | 1971-04-09 | 1972-08-29 | Fairfied Mfg Co Inc | Plantetary reduction wheel hub |
GB1438940A (en) * | 1972-07-19 | 1976-06-09 | Glaxo Lab Ltd | 17beta-haloalkoxycarbonyl-17alpha-oxysteroids |
US4093721A (en) * | 1974-08-30 | 1978-06-06 | Glaxo Laboratories Limited | Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof |
GB1514476A (en) | 1974-08-30 | 1978-06-14 | Glaxo Lab Ltd | Alkyl and haloalkyl androst-4-ene and androsta-1,4-diene-17beta-carboxylates |
GB2137206B (en) | 1980-02-15 | 1985-04-03 | Glaxo Group Ltd | Androstane 17-carbothioc acid derivatives |
SE449106B (sv) | 1980-07-10 | 1987-04-06 | Otsuka Pharma Co Ltd | Steroid med anti-inflammatorisk verkan samt komposition innehallande denna |
US4996335A (en) * | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
EP0334853B1 (en) | 1987-10-13 | 1993-06-09 | BODOR, Nicholas S. | Soft steroids having anti-inflammatory activity |
US5990099A (en) | 1988-10-31 | 1999-11-23 | Alcon Laboratories, Inc. | Angiostatic agents and methods and compositions for controlling ocular hypertension |
GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
AU677776B2 (en) | 1992-04-02 | 1997-05-08 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
EP0765308B1 (en) | 1994-06-15 | 2000-04-05 | The Wellcome Foundation Limited | Enzyme inhibitors |
US6172054B1 (en) | 1995-06-15 | 2001-01-09 | Alcon Laboratories, Inc. | Combination therapy for lowering and controlling intraocular pressure |
AU1970197A (en) | 1996-05-09 | 1997-11-26 | Alcon Laboratories, Inc. | Use of steroid compounds to prevent non-cancerous tissue growth |
MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
US6245804B1 (en) | 1997-05-30 | 2001-06-12 | Schering Aktiengesellschaft | Nonsteroidal gestagens |
DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
WO1999016766A1 (fr) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Derives de benzodioxole |
CA2306026A1 (en) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Benzofuran derivatives as phosphodiesterase iv inhibitors |
US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
WO1999047505A1 (en) | 1998-03-14 | 1999-09-23 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phthalazinone pde iii/iv inhibitors |
GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
CA2371273A1 (en) | 1999-05-04 | 2000-11-09 | Andrew Fensome | Tetracyclic progesterone receptor modulator compounds and methods |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
US6263209B1 (en) | 1999-07-28 | 2001-07-17 | Motorola, Inc. | Method and apparatus in a wireless communication system for creating a learning function |
CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
GB0015876D0 (en) * | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
AR032361A1 (es) * | 2000-08-05 | 2003-11-05 | Glaxo Group Ltd | Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos |
AR035205A1 (es) | 2000-09-29 | 2004-05-05 | Glaxo Group Ltd | Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas |
JP2004522711A (ja) | 2000-11-16 | 2004-07-29 | アルコン マニュファクチャリング,リミティド | 眼内圧の低下および制御のための組み合わせ治療 |
GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
DE60224172T2 (de) | 2001-03-22 | 2008-12-04 | Glaxo Group Ltd., Greenford | Formanilid-derivative als beta2-adrenorezeptor-agonisten |
JP4446661B2 (ja) * | 2001-04-30 | 2010-04-07 | グラクソ グループ リミテッド | 抗炎症性の、17α位に環状エステル基を有するアンドロスタンの17β−カルボチオ酸エステル誘導体 |
NZ531651A (en) | 2001-09-14 | 2006-02-24 | Glaxo Group Ltd | Phenethanolamine derivatives for treatment of respiratory diseases |
GB0125259D0 (en) * | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
US6960581B2 (en) | 2002-01-14 | 2005-11-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof |
WO2003072592A1 (en) * | 2002-01-15 | 2003-09-04 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
US6831093B2 (en) | 2002-01-22 | 2004-12-14 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
WO2003082280A1 (en) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
CA2477764A1 (en) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
US6897224B2 (en) | 2002-04-02 | 2005-05-24 | Schering Ag | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors |
US7282591B2 (en) | 2002-04-11 | 2007-10-16 | Merck & Co., Inc. | 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
WO2003091204A1 (en) | 2002-04-25 | 2003-11-06 | Glaxo Group Limited | Phenethanolamine derivatives |
US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
AU2003281355A1 (en) | 2002-07-08 | 2004-01-23 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
AU2003251970A1 (en) | 2002-07-18 | 2004-02-09 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
US7442554B2 (en) | 2002-07-18 | 2008-10-28 | Bristol-Myers Squibb Company | Compositions and methods involving glucocorticoid receptor site II |
GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
DE60322713D1 (de) | 2002-08-21 | 2008-09-18 | Boehringer Ingelheim Pharma | Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung |
GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
US20060089375A1 (en) | 2002-09-16 | 2006-04-27 | Allen David G | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors |
WO2004026248A2 (en) | 2002-09-20 | 2004-04-01 | Merck & Co., Inc. | Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
AU2003298094A1 (en) | 2002-10-22 | 2004-05-13 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
US7442839B2 (en) | 2002-10-28 | 2008-10-28 | Glaxo Group Limited | Phenethanolamine derivative for the treatment of respiratory diseases |
GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
GB0316290D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
-
2003
- 2003-07-11 GB GBGB0316290.6A patent/GB0316290D0/en not_active Ceased
-
2004
- 2004-07-08 AR ARP040102427A patent/AR045900A1/es unknown
- 2004-07-08 AR ARP040102428A patent/AR045901A1/es unknown
- 2004-07-09 CN CN2004800255908A patent/CN1845933B/zh not_active Expired - Fee Related
- 2004-07-09 BR BRPI0412526-6A patent/BRPI0412526A/pt not_active Application Discontinuation
- 2004-07-09 KR KR1020067000690A patent/KR101029207B1/ko active IP Right Grant
- 2004-07-09 RU RU2005141226/04A patent/RU2359973C2/ru active
- 2004-07-09 RU RU2005141064/04A patent/RU2348645C2/ru active
- 2004-07-09 WO PCT/EP2004/007820 patent/WO2005005452A1/en active Application Filing
- 2004-07-09 PL PL04741020T patent/PL1644397T3/pl unknown
- 2004-07-09 WO PCT/EP2004/007819 patent/WO2005005451A1/en active Application Filing
- 2004-07-09 CN CN2011102290522A patent/CN102372756A/zh active Pending
- 2004-07-09 CN CN2004800256690A patent/CN1849330B/zh not_active Expired - Fee Related
- 2004-07-09 TW TW093120698A patent/TWI367888B/zh not_active IP Right Cessation
- 2004-07-09 ES ES11151276T patent/ES2433665T3/es active Active
- 2004-07-09 SI SI200432006T patent/SI1644398T1/sl unknown
- 2004-07-09 AU AU2004255855A patent/AU2004255855B2/en not_active Ceased
- 2004-07-09 NZ NZ544577A patent/NZ544577A/en unknown
- 2004-07-09 DK DK04741020.4T patent/DK1644397T3/da active
- 2004-07-09 EP EP04741020A patent/EP1644397B1/en active Active
- 2004-07-09 KR KR1020067000738A patent/KR101075324B1/ko active IP Right Grant
- 2004-07-09 US US10/564,299 patent/US7291609B2/en active Active
- 2004-07-09 MY MYPI20042752A patent/MY137944A/en unknown
- 2004-07-09 EP EP11151276.0A patent/EP2380898B1/en active Active
- 2004-07-09 DK DK04763226.0T patent/DK1644398T3/da active
- 2004-07-09 ES ES04763226T patent/ES2400821T3/es active Active
- 2004-07-09 MY MYPI20042746A patent/MY140987A/en unknown
- 2004-07-09 DE DE602004027137T patent/DE602004027137D1/de active Active
- 2004-07-09 NZ NZ544576A patent/NZ544576A/en unknown
- 2004-07-09 US US10/564,325 patent/US7288536B2/en active Active
- 2004-07-09 MX MXPA06000443A patent/MXPA06000443A/es active IP Right Grant
- 2004-07-09 AU AU2004255854A patent/AU2004255854B2/en not_active Ceased
- 2004-07-09 JP JP2006518181A patent/JP4709752B2/ja not_active Expired - Fee Related
- 2004-07-09 BR BRPI0412527-4A patent/BRPI0412527A/pt not_active Application Discontinuation
- 2004-07-09 ES ES04741020T patent/ES2343685T3/es active Active
- 2004-07-09 PL PL04763226T patent/PL1644398T3/pl unknown
- 2004-07-09 SI SI200431471T patent/SI1644397T1/sl unknown
- 2004-07-09 CA CA2531905A patent/CA2531905C/en not_active Expired - Fee Related
- 2004-07-09 CA CA2531911A patent/CA2531911C/en not_active Expired - Fee Related
- 2004-07-09 PT PT04741020T patent/PT1644397E/pt unknown
- 2004-07-09 MX MXPA06000442A patent/MXPA06000442A/es active IP Right Grant
- 2004-07-09 AT AT04741020T patent/ATE467638T1/de active
- 2004-07-09 EP EP04763226A patent/EP1644398B1/en active Active
- 2004-07-09 TW TW093120707A patent/TWI338694B/zh not_active IP Right Cessation
- 2004-07-09 JP JP2006518180A patent/JP4709751B2/ja not_active Expired - Fee Related
- 2004-07-09 PT PT47632260T patent/PT1644398E/pt unknown
-
2005
- 2005-12-22 IL IL172777A patent/IL172777A/en active IP Right Grant
- 2005-12-22 IS IS8193A patent/IS2909B/is unknown
- 2005-12-22 IS IS8194A patent/IS2776B/is unknown
- 2005-12-22 IL IL172776A patent/IL172776A/en active IP Right Grant
-
2006
- 2006-01-06 MA MA28703A patent/MA27899A1/fr unknown
- 2006-01-06 NO NO20060111A patent/NO333263B1/no not_active IP Right Cessation
- 2006-01-06 NO NO20060110A patent/NO332041B1/no not_active IP Right Cessation
- 2006-01-06 MA MA28701A patent/MA27897A1/fr unknown
- 2006-01-10 ZA ZA200600226A patent/ZA200600226B/en unknown
- 2006-01-10 ZA ZA200600223A patent/ZA200600223B/en unknown
- 2006-08-29 HK HK06109622.1A patent/HK1089186A1/xx not_active IP Right Cessation
- 2006-08-29 HK HK06109621.2A patent/HK1089185A1/xx not_active IP Right Cessation
-
2007
- 2007-09-28 US US11/863,390 patent/US7638508B2/en active Active
- 2007-09-28 US US11/863,419 patent/US20080021231A1/en not_active Abandoned
- 2007-09-28 US US11/863,439 patent/US7524970B2/en active Active
-
2009
- 2009-04-03 RU RU2009112207/04A patent/RU2009112207A/ru not_active Application Discontinuation
-
2010
- 2010-03-01 US US12/714,961 patent/US20100152148A1/en not_active Abandoned
- 2010-06-29 HR HR20100359T patent/HRP20100359T1/hr unknown
- 2010-06-30 CY CY20101100601T patent/CY1110149T1/el unknown
- 2010-12-23 IL IL210209A patent/IL210209A0/en unknown
-
2011
- 2011-01-07 JP JP2011001699A patent/JP2011093929A/ja active Pending
-
2013
- 2013-01-23 HR HRP20130056TT patent/HRP20130056T1/hr unknown
- 2013-03-19 CY CY20131100230T patent/CY1113836T1/el unknown
-
2014
- 2014-10-28 IS IS050094A patent/IS2928B/is unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI338694B (en) | Novel compounds | |
JP5281291B2 (ja) | 新規化合物 | |
EP1836215B1 (en) | Androstane 17-alpha-carbonate for use in the treatment of inflammatory and allergic conditions | |
JP2009515844A (ja) | 17アルファ−カルボネート置換基を有する17ベータ−フルオロメトキシカルボニル−アンドロスタ−4−エン−3−オン化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |